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Introduction
Global preterm birth and stillbirth rates may be improved 
with interventions directed toward women before and 
during pregnancy, labor and birth. Such interventions, 
along with those given to preterm newborns, may also 
improve preterm survival and other maternal, newborn 
and child health (MNCH) outcomes. Nearly 50 existing 
interventions are discussed in this article, and were 
selected on the basis of available evidence of impact, 
ability to be used in low- and middle-income countries 
(LMICs), and other factors discussed below. Th  ey are 
organized by stage and recipient:
Abstract
Introduction: Interventions directed toward mothers before and during pregnancy and childbirth may help reduce 
preterm births and stillbirths. Survival of preterm newborns may also be improved with interventions given during 
these times or soon after birth. This comprehensive review assesses existing interventions for low- and middle-
income countries (LMICs).
Methods: Approximately 2,000 intervention studies were systematically evaluated through December 31, 2008. They 
addressed preterm birth or low birth weight; stillbirth or perinatal mortality; and management of preterm newborns. 
Out of 82 identifi  ed interventions, 49 were relevant to LMICs and had reasonable amounts of evidence, and therefore 
selected for in-depth reviews. Each was classifi  ed and assessed by the quality of available evidence and its potential 
to treat or prevent preterm birth and stillbirth. Impacts on other maternal, fetal, newborn or child health outcomes 
were also considered. Assessments were based on an adaptation of the Grades of Recommendation Assessment, 
Development and Evaluation criteria.
Results: Most interventions require additional research to improve the quality of evidence. Others had little evidence 
of benefi  t and should be discontinued. The following are supported by moderate- to high-quality evidence and 
strongly recommended for LMICs:
•  Two interventions prevent preterm births—smoking cessation and progesterone
•  Eight interventions prevent stillbirths—balanced protein energy supplementation, screening and treatment of 
syphilis, intermittant presumptive treatment for malaria during pregnancy, insecticide-treated mosquito nets, birth 
preparedness, emergency obstetric care, cesarean section for breech presentation, and elective induction for post-
term delivery
•  Eleven interventions improve survival of preterm newborns—prophylactic steroids in preterm labor, antibiotics for 
PROM, vitamin K supplementation at delivery, case management of neonatal sepsis and pneumonia, delayed cord 
clamping, room air (vs. 100% oxygen) for resuscitation, hospital-based kangaroo mother care, early breastfeeding, 
thermal care, and surfactant therapy and application of continued distending pressure to the lungs for respiratory 
distress syndrome
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© 2010 BioMed Central LtdInterventions directed toward the mother to prevent 
preterm birth or stillbirth
• Before  pregnancy
• During  pregnancy
• Pregnancy  infections
• High-risk  pregnancies
•  Intrapartum interventions to prevent stillbirth
Interventions to improve preterm survival
•  Intrapartum interventions given to the mother
•  Postpartum interventions directed toward the preterm 
newborn
Th  is article discusses the evidence base for these inter-
ventions, and gives special reference to LMICs. A 
recommendation is provided for each intervention. 
When available, the evidence is assessed for preterm 
birth, stillbirth, preterm survival and other MNCH 
outcomes.
Th  is is the third article in a global report on preterm 
birth and stillbirth. Th  e ﬁ   rst two articles describe the 
deﬁ  nitions, data and known causes [1, 2]. Th  e next few 
articles discuss scaling up proven interventions, advocacy 
barriers and opportunities, and ethical considerations 
relating to these issues [3-5]. Th   e concluding article presents 
recommendations for a Global Action Agenda [6].
Methods
Th  is review systematically evaluates interventions to 
prevent preterm birth and stillbirth, and to improve 
survival among preterm newborns. More than 80 
biologically plausible interventions were initially selected 
(Table 1). Figure 1 illustrates the ﬁ  nal selection process 
for the 49 interventions included in this review.
Approximately 2,000 studies were reviewed on inter-
ventions addressing preterm birth (or low birth weight), 
stillbirth (or perinatal mortality), and preterm survival. 
Th  is number includes systematic reviews and meta-
analyses, along with stand-alone papers from observa-
tional or experimental studies. Interventions with a bene-
ﬁ   cial impact on other maternal, newborn and child 
health outcomes, but that did not inﬂ  uence preterm birth 
or stillbirth outcomes, were not considered.
Th  e search engines used were PubMed and Th  e 
Cochrane Library. Search terms included “stillbirth*,” 
“perinatal mortality,” “fetal death*,” “preterm*,” “low birth 
weight“and “low birthweight.” Targeted search terms 
were also used for each intervention (e.g., “iron” AND 
“supplementation” AND “pregnancy”; and “cervical 
cerclage” AND “pregnancy”), with humans as limits. 
Th   ese terms are deﬁ  ned in article 1 of this global report [1].
Th   e last search date was December 31, 2008. (Note that 
papers published after this date may inﬂ  uence  key 
ﬁ   ndings in this article.) Th  e emphasis was to identify 
randomized and quasi-randomized study designs. Where 
such trials were not available, observational studies were 
included. When a high-quality meta-analysis was avail-
able, it served as the basis for the review, and was updated 
with results of more recent studies when available.
Perinatal mortality studies are also considered, as some 
did not separate stillbirths from overall perinatal 
mortality. Few studies distinguished between antepartum 
and intrapartum stillbirths. Studies reporting on overall 
low birth weight rates, or mean birth weights, are also 
included when preterm birth was not reported as a 
separate outcome.
For each intervention, an adaptation of the Grades of 
Recommendation Assessment, Development and Evalua-
tion (GRADE) criteria [7, 8] was used to rate the level of 
available evidence into either high, moderate, low or very 
low (see Table 2).
Th  e GRADE system starts from a pre-established 
quality of evidence rating for each type of study design, 
but allows ﬂ   exibility for lowering or increasing this 
rating. For example, results from randomized controlled 
trials (RCTs) may be downgraded from “high” to 
“moderate” quality if there are methodological short-
comings such as lack of precision, the possibility of 
reporting bias or other limitations to study quality. On 
the other hand, results from observational studies may be 
upgraded from “low” to “moderate” if the studies are 
particularly strong (e.g., when confounding variables are 
unlikely or when there is a dose-response gradient).
Th   e original GRADE system requires individual ratings 
for each study included in the review. Th   e overall rating 
provided in this review is based on the collective 
appraisal of all publications on each intervention, since it 
was largely based on existing meta-analyses or on fresh 
pooled analyses carried out for stillbirth interventions 
and some preterm postnatal interventions.
A major advantage of the GRADE system, compared to 
other classiﬁ  cations, is it provides a practical recommen-
dation regarding each intervention, assessing the extent 
to which one can be conﬁ  dent adherence to a recommen-
dation will do more good than harm. Th  e  recommenda-
tion is based on the quality of evidence, how the evidence 
may be translated to practice in a speciﬁ  c setting such as 
LMICs, the level of baseline risk, and on potential trade-
oﬀ  s between expected beneﬁ  ts, harms and costs.
Th  e recommendation for each intervention was then 
placed in one of the following categories:
•  Strong in favor
•  Weak in favor
• Weak  against
• Strong  against
Recommendations against the intervention does not 
neces  sarily indicate there is evidence the intervention 
does harm; such recommendations most often reﬂ  ect no 
evidence of beneﬁ  t, and due to the costs incurred there 
are no reasons for further implementation.
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Selected Interventions  Selected Interventions
X indicates interventions described in the text. Interventions without the X were reviewed but not included due to one or more of the following reasons: (a) the 
available evidence was very limited; (b) there was no evidence of an impact; (c) the intervention requires high technology; (d) the intervention is seldom used; (e) the 
intervention was applicable to a small subgroup of pregnant women.
Group 1: Interventions given before pregnancy
 X  Birth  spacing
 X  Periconceptional  folate
  X  Indoor air pollution control
    Prevention of female genital mutilation
Group 2: Interventions given during pregnancy
  X  Smoking cessation programs
  X  Balanced protein energy supplementation
  X  Multiple micronutrient supplementation 
  X  Iron and folate supplementation
 X  Zinc  supplementation
  X  Magnesium sulfate supplementation 
 X  Calcium  supplementation
  X  Supplementation with long-chain polyunsaturated fatty acids
 X  Cardiotocographic  monitoring
  X  Doppler and late ultrasound monitoring
    Anti-platelet agents in pregnancy, including aspirin
   Anti-malarials
   Anti-oxidants
    Vitamin A/Beta-Carotene supplementation
Group 3: Interventions for pregnancy infections
  X  Screening and treatment of syphilis 
  X  Intermittent presumptive treatment during pregnancy (IPTp) for 
   malaria
  X  Insecticide-treated mosquito nets (ITNs)
  X  Screening and treatment of asymptomatic bacteriuria 
  X  Screening and treatment of bacterial vaginosis 
  X  Prevention of mother-to-child transmission of HIV
 X  Anti-helminthic  treatment
  X  Screening and treatment of periodontal disease 
Group 4: Interventions for pregnancies with high-risks of PTB or SB
 X  Progesterone
 X  Cervical  cerclage
  X  Multivitamins for HIV+ women
    Amniotic fl  uid volume assessment
    Antepartum fetal heart rate monitoring with cardiotocography
    Cervical pessaries to prevent preterm birth
    Fetal biophysical test scoring 
    Home versus hospital monitoring for high-risk pregnancies
    In-hospital fetal surveillance unit
    Intrapartum cardiotocography and pulse oximetry
    Management of gestational diabetes mellitus
    Non stress testing or vibroacoustic stimulation
    Use of the partograph
    Fetal movement monitoring
    Heparin in pregnancy
    Management of intrahepatic cholestasis
   Pelvimetry 
   Plasma  exchange
    Pregnancy risk screening
   Ultrasound  scanning
Group 5: Intrapartum interventions to prevent stillbirth
 X  Birth  preparedness
  X  Use of partogram
  X  Fetal movement monitoring
  X  Emergency obstetric care 
  X  Cesarean section for breech presentation
  X  Elective induction of labor for post-term delivery
  X  Elective induction of term PROM
  X  Home delivery vs. facility delivery
    Instrumental deliveries (forceps versus vacuum)
   Amnioinfusion
    Cervical ripening and induction of labor with diff  erent 
   prostaglandins
    COX inhibitors for preterm labor
    Magnesium sulphate for treatment of preeclampsia/eclampsia or 
   preterm  labor
   Maternal  hyperoxygenation
Group 6: Antepartum and intrapartum interventions to improve preterm 
survival
  X  Prophylactic corticosteroid therapy in preterm labor
  X  Antibiotics for PROM/PPROM 
  X  Antibiotics for preterm labor with intact membranes
  X  Delayed cord clamping
    Vitamin A to the mother
Group 7: Postnatal interventions to improve preterm survival
 X  Neonatal  resuscitation
  X  Vitamin A supplementation
  X  Vitamin K supplementation
 X  Zinc  supplementation
 X  Selenium  supplementation
  X  Chlorhexidine treatment on the cord
  X  Case management of neonatal sepsis and pneumonia
  X  Kangaroo mother care (KMC)
 X  Early  breastfeeding
 X  Thermal  care
  X  Application of continued distending pressure or CPAP to the 
    lungs for RDS
  X  Intravenous immune globulin (IVIG) 
  X  Surfactant therapy for RDS
   Emollient  therapy
   Hand  washing
    Prophylaxis of eye infection 
    Use of Appropriate Low-cost Technology (incubators, techniques 
    for minimally invasive intravenous access, protection against the 
    excessive use of oxygen)
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not only for the main outcomes in this review, but also 
for the intervention’s impact on other MNCH outcomes 
when relevant. For many interventions, the recommen-
dations for preventing stillbirth or preterm birth conﬂ  ict 
with the recommendation for overall MNCH outcomes. 
Th  is will be further discussed in the next article on the 
delivery of interventions.
Results
Th   e 49 interventions reviewed below are classiﬁ  ed accord-
ing to service delivery strategies across the continuum of 
care. Table 1 shows all interventions considered in this 
review. Th   e narrative below is restricted to interventions 
for which a reasonable amount of evidence is present, 
and, or, those relevant to low- and middle-income 
countries. Th  is review of the evidence indicates a 
remarkable paucity of data on preterm birth and stillbirth 
for many potentially relevant interventions.
Table  3 summarizes the assessment of the quality of 
evidence and level of recommendation for each 
intervention using the GRADE system. Th  ese  recom  men-
dations consider the preterm birth and stillbirth outcomes, 
as well as other important maternal and neonatal 
outcomes. It is important to note that most studies 
reviewed lacked statistical power to pick up as statistically 
signiﬁ  cant an eﬀ  ect on stillbirth, as their main outcomes 
were more frequently pregnancy and childbirth-related 
conditions. In addition, many studies—particularly from 
LMICs—did not report on preterm birth as an outcome.
Interventions given before pregnancy
Birth spacing
A number of hypotheses explain why short or long birth 
intervals could aﬀ  ect perinatal health. For short intervals, 
maternal nutrition depletion is the most often proposed; 
women do not have time to recover from the expenses 
related to pregnancy and lactation before getting preg-
nant again. For long intervals, the reasons are less clear, 
but it appears reproductive capacity declines after 
delivery, and that diseases aﬀ   ecting the mother could 
have an eﬀ  ect on both fertility and the health of the baby 
[9]. Optimally-spaced births can potentially reduce fetal 
and maternal morbidity and mortality.
Access to modern family planning methods is still 
problematic in many low-income countries [10]. It is 
Figure 1. Intervention selection process.
82 Preterm Birth and Stillbirth Interventions Initially Identified 
Evidence available? 
Evidence of impact? 
Requires low or no technology?
Can be or is used in LMICs? 
Applicable to wide group of pregnant women? 
Yes No: Not Selected 
Yes
Yes
Yes
Yes
No: Not Selected 
No: Not Selected 
No: Not Selected 
No: Not Selected 
49 Interventions Included in Review 
Table 2. GRADE Criteria for Quality of Evidence
Quality of Evidence  Study Design  Interpretation
High  Randomized Controlled Trials (RCTs)  Further research is very unlikely to change our confi  dence in the estimate of eff  ect.
Moderate  Low-Quality Randomized Trials or   Further research is likely to have an important impact on our confi  dence in the
  High-Quality Observational Studies  estimate of eff  ect and may change the estimate.
Low  Observational Studies  Further research is very likely to have an important impact on our confi  dence in the 
    estimate of eff  ect and is likely to change the estimate.
Very Low  Any Other Evidence  Any estimate of eff  ect is very uncertain.
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  Quality of evidence  Recommendation for implementation
Intervention        Other  MNCH      Other  MNCH
(by stage or recipient)  SB  PMR  PTB  LBW  Outcomes  SB/PMR  PTB  LBW  Outcomes
Interventions given before pregnancy
Birth  Spacing  Low  Mod Mod* Mod* Mod* Weak  Weak Weak  Strong: 
            Maternal  and 
            Child  Mortality
Periconceptional Folate  Mod  Mod  Low  Low  High  Weak  Weak  Weak  Strong: Neural
         Against     Tube  Defects
Indoor Air Pollution Control  Low  -  Very   Low  High  Weak  Weak  Weak  Strong: 
     Low**      Against    Respiratory 
            Infections
Interventions given during pregnancy
Smoking Cessation Programs  Low  Low  High  High  High  Weak  Strong  Strong  Strong: 
            Smoking-Related 
            Diseases
Balanced Protein Energy   High  -  High  High  -  Strong  Strong    Strong: Infant
Supplementation     No  Eff  ect        Against  Strong  Mortality
Multiple Micronutrient   High  Mod  High  High  High  Weak  Strong  Strong  Weak Against: 
Supplementation No  Eff  ect    No Eff  ect    (Maternal   Against  Against    Neonatal
        Anemia,  IMR)      Mortality
Iron and Folate  Mod   Mod   Mod   Mod   High  Weak  Weak  Weak  Strong: Anemia
Supplementation No  Eff  ect**  No Eff  ect**  No Eff  ect**  No Eff  ect**  (Maternal  Against  Against  Against 
        Anemia)
Zinc Supplementation  High   High   High  High  Mod  Strong  Weak  Strong  Weak
 No  Eff  ect  No Eff  ect   High  No Eff  ect   (Reduced  Against    Against
        C-Sections)
Magnesium Sulfate   High  High  Mod**  Mod**  High  Strong  Weak  Weak  Weak: 
Supplementation        (Cerebral  Palsy)  Against  Against  Against  Supplementation 
            Strong:  Treatment 
            of  Eclampsia  and 
            Prevention  of 
            Cerebral  Palsy
Calcium Supplementation  High  -  Mod  Mod  High  Strong  Weak  Weak  Strong: 
 No  Eff   ect      (Preeclampsia)  Against     Preeclampsia
Supplementation  with  -  - High  High -  -  Strong  Strong  -
Fatty Acids      No Eff  ect  No Eff  ect      Against  Against
Cardiotocographic    Low  Mod -     Weak    
Monitoring
Doppler and Late   High    -  -    Strong  -  - 
Ultrasound Monitoring  No Eff   ect       Against
Pregnancy infections
Screening and Treatment   Mod*  Very   Mod*  Mod*  Mod*  Strong  Weak  Weak  Strong: Congenital
of Syphilis      Low**              Syphilis
Intermittent Presumptive   Mod  High  Low**  High  High  Strong  Weak  Strong  Strong: Maternal
Treatment During Pregnancy                   Malaria
(IPTp) for malaria        
Insecticide-Treated   High  -  Low**  High  High  Strong  Weak  Strong  Strong: Maternal
Mosquito Nets (ITNs)               Against    Malaria
Screening and Treatment   **  **  Low**  High  High  -  Weak  Strong  Strong: 
of Asymptomatic Bacteriuria           (Maternal        Pyelonephritis, 
        Morbidity)      Maternal  Morbidity
Screening and Treatment   -  -  High  High  -  -  Strong  Strong  -
of Bacterial Vaginosis       No Eff  ect  No Eff  ect      Against  Against
Prevention of Mother-to-  Low  Low  Low  -  High  **  **  **  Strong: PMTCT
Child Transmission of HIV          (PMTCT)
Continued overleaf
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  Quality of evidence  Recommendation for implementation
Intervention        Other  MNCH      Other  MNCH
(by stage or recipient)  SB  PMR  PTB  LBW  Outcomes  SB/PMR  PTB  LBW  Outcomes
Pregnancy infections (continued)
Anti-Helminthic  Treatment  Low  Low Low Low High  Weak  Weak  Weak  Strong:  Maternal
        (Maternal  Against  Against  Against  Anemia
        Hookworm)     
Screening and Treatment of   -  -  Mod**  Mod**  Low    Weak  Weak  Weak: Maternal
Periodontal  Disease        (Maternal    Against  Against  Oral  Health
        Oral  Health)     
Interventions for pregnancies with high-risks of preterm birth or stillbirth
Progesterone Mod    High  High  -  Weak  Strong  Strong  -
         Against
Cervical  Cerclage  High   High   - Weak  Strong  -  -
 No  Eff  ect    No Eff  ect      Against  Against   
Multivitamins for  Low  Low  Mod  Mod  -  Weak  Weak  Weak  -
HIV+ Women      No Eff  ect  No Eff  ect    Against  Against  Against 
Intrapartum interventions to prevent stillbirths
Birth Preparedness  High  Mod  -  -    Strong  -  - 
Use of Partogram  Low  Low  -  -    Weak  -  - 
Fetal Movement Monitoring  Low  -  -  -    Strong Against  -  - 
Emergency Obstetric Care  Mod*  Mod*  -  -  Mod  Strong  -  -  Strong: Maternal 
        (Maternal      Mortality
        Outcomes)
Cesarean Section for   -  High  -  -    Strong  -  - 
Breech Presentation
Elective Induction for   Mod  High  -  -    Strong  -  - 
Post-Term Delivery
Elective Induction     Mod      High  Weak      Strong: Maternal
for Term PROM          (Maternal and        and Infant
        Infant  Outcomes)      Outcomes
Home Delivery    Mod  -  -    Weak 
         Against    
Intrapartum interventions to improve preterm survival
Prophylactic Steroids in   -  -  High  -  High  -  Strong  -  Strong: Neonatal
Preterm  Labor        (Neonatal      Morbidity
        Morbidity)
Antibiotics  for  PROM  -  - High - High   Strong    Strong:  Neonatal 
        (Neonatal      Morbidity
        Morbidity)
Antibiotics for Preterm   -  -  High  -      Strong   
Labor with Intact Membranes              Against
Delayed cord clamping      High        Strong   
Postnatal interventions to improve preterm survival
Neonatal  Resuscitation           
• Modes of oxygen delivery       Low    -    -    -
  and resuscitation 
  techniques: CPR
• Modes of delivery and       Mod    -    -    -
  techniques: bag and mask
• CPR techniques: long- &       Low    -    -    -
  short-term outcomes
• Room air (vs. 100% oxygen)       High    -    Strong    -
  for resuscitation
Continued overleaf
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high birth rates could reduce one third of maternal 
deaths and 10% of childhood mortality [11]. After a birth, 
the interval before attempting a new pregnancy should 
be at least 24 months to reduce the risk of adverse 
maternal and infant outcomes [12].
Preterm birth
A meta-analysis of observational studies [9] showed a 
40% increase in preterm births when the birth interval 
was shorter than 6 months, relative to babies born after a 
birth interval of 18-23 months (RR 1.40; CI 1.24–1.58). 
Th   e corresponding odds ratios were 1.61 (95% CI 1.39–
1.86) for low birth weight and 1.26 (95% CI 1.18–1.33) for 
IUGR. A 20% increase in preterm births was also found 
when the birth interval was 60 months or longer (OR 
1.20; 95% CI 1.17–1.24). Th  ere are no intervention 
studies, however, showing that promoting birth spacing 
will reduce either preterm births or low birth weight.
Stillbirth
Stephansson et al. [13], using a logistic regression analysis 
on the Swedish registry data, showed that compared with 
interpregnancy intervals (IPIs) 12–25 months, very short 
IPIs (0–3 months) were linked to an increased risk of 
stillbirth, though nonsigniﬁ  cant (adjusted OR = 1.3; 95% 
CI: 0.8–2.1). IPIs greater than 72 months also increased 
women’s risk of stillbirth in this study (adjusted OR = 1.5; 
Table 3. Continued
  Quality of evidence  Recommendation for implementation
Intervention        Other  MNCH      Other  MNCH
(by stage or recipient)  SB  PMR  PTB  LBW  Outcomes  SB/PMR  PTB  LBW  Outcomes
Postnatal interventions to improve preterm survival (continued)
Training programs for       Mod    -    Weak    -
health facilities
Vitamin A supplementation      Mod    -    Weak    -
          Against
Vitamin  K  supplementation     Mod  Mod   Strong    Weak: 
        (antenatal)      antenatal
Zinc  supplementation     Low   -   Weak    -
          Against
Selenium  supplementation     Mod   -   Weak    -
Chlorhexidine treatment       Mod    -    -    -
on the cord
Case management of       Mod    -    Strong    -
neonatal sepsis and pneumonia
Kangaroo mother care (KMC)                 
Hospital-based  KMC     High   -    Strong    -
Community-based  KMC     Low   -    -    -
Early  breastfeeding     High  Mod   Strong    -
        (neonatal
        mortality)
Thermal care (skin to skin;       Mod    -    Strong    -
plastic wraps)
Application of continued       High    High    Strong    Strong: 
distending pressure to the            (reducing chronic         bronchopulmonary
lungs for RDS          lung disease, and         dysplasia
        as  alternative  to 
        intubation) 
        Low  pneumothorax     
Intravenous immune       High        Weak   
globulin (IVIG)
Surfactant  therapy       High  High   Strong    Strong
for  RDS        (reducing  chronic 
        lung  disease)
(*) Due to ethical issues, RCTs are not possible.
(**) Limited evidence, or outcomes not reported.
(-) Not applicable or no evidence
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between increased risk of fetal loss and short or long IPIs 
[14, 15].
Assessment
Th   e quality of evidence relating birth spacing to preterm 
birth and low birth weight is moderate, as it is based on a 
large number of carefully conducted observational 
studies. While it is not expected that randomized trials 
will be conducted on the value of birth spacing in the 
future, there is a critical need for evaluating the eﬀ  ective-
ness of various strategies to promote birth spacing, 
induced terminations and prevention of unwanted preg-
nancies [16]. Th   e level of recommendation is, there  fore, 
weak in favor of this intervention to prevent preterm 
birth and low birth weight.
Th  e overall quality of evidence of the impact of birth 
spacing on perinatal mortality is moderate, but data on 
stillbirths are sparse. Th   erefore, this intervention has low 
evidence of beneﬁ   t for preventing stillbirth and the 
recommendation is weak in favor of its use for this 
outcome. Further evaluation of interventions promoting 
birth spacing is needed with reference to stillbirth 
outcomes. However, birth spacing is strongly recom-
mended due to its important eﬀ  ects on both maternal 
and child health outcomes [12].
Periconceptional folate
Folic acid is a key element involved in DNA metabolism 
and necessary for red cell formation and correct closure 
of the neural tube. Almost all people who do not consume 
supplemental folic acid are folate deﬁ   cient, and peri-
conceptional folate supplementation reduces neural tube 
defects by 50-70% [17]. It is calculated that a 90% 
coverage of folate use in low- and middle-income 
countries would reduce nearly 80% of such defects [18].
Preterm birth
No intervention studies show an eﬀ   ect of peri-
conceptional folate supplementation on preterm birth 
or low birth weight. Th   ree observational studies 
conducted in the United States were identiﬁ  ed in this 
review. Th  e ﬁ   rst found a two-fold increased risk of 
preterm birth and low birth weight in women with low 
daily folate intake and low serum folate levels at 28 
weeks of gestation [19]. Another observational study, 
conducted before and after folate fortiﬁ  cation programs 
in California, found small reductions in adjusted risks 
after the fortiﬁ   cation for low birth weight (RR 0.94; 
0.93–0.96) and preterm birth (RR 0.96; 0.94–0.97) [20]. 
A third observational study [21] showed that 
preconceptional folate supplementation for longer than 
one year was associated with a reduced incidence of 
spontaneous preterm birth between 28 and 32 weeks 
(hazard ratio 0.45, 0.23–0.85), but no signiﬁ  cant eﬀ  ect 
was noted between 32-36 weeks of gestation.
Stillbirth
A Cochrane review, including three trials that reported 
perinatal outcomes, concluded that periconceptional 
folic acid supplementation is of proven beneﬁ  t in reduc-
ing neural tube defects, reﬂ  ected by a statistically signi-
ﬁ  cant reduction in its rate (RR 0.28; 95% CI 0.13–0.58), 
but impact on stillbirths is that of a 22%, nonsigniﬁ  cant 
reduction (RR 0.78; 95% CI 0.34–1.78) [22].
Assessment
Th  e quality of evidence is low for preterm birth, but 
because the three observational studies point in the same 
direction, the recommendation is weak in favor of the 
intervention. Th  e quality of evidence is moderate for 
stillbirths given the wide uncertainty in the results; the 
intervention cannot be recommended exclusively for 
prevent  ing stillbirth and thus received a weak recom-
mendation against the intervention for this outcome. 
Nevertheless, periconceptional folate is strongly recom-
mended for other MNCH outcomes due to its protective 
eﬀ  ect on neural tube defects. Further studies are needed 
to assess potential long-term beneﬁ   ts of folic acid 
supplementation during pregnancy.
Indoor air pollution
Th  e daily energy needs of around 50% of the world’s 
popu  lation are met by the burning of solid fuels [23]. 
Cooking is usually the domain of women, especially in 
developing countries even during pregnancy. Th  eir 
homes are usually crowded and poorly ventilated, 
leading to intense smoke exposure that could harm the 
growing fetus as smoke metabolites cross the placental 
barrier.
Preterm birth
Observational studies in Guatemala, Pakistan and 
Zimbabwe show an association between this practice and 
decreased birth weight, but no information is available 
on preterm births [24, 25] . In addition, no intervention 
studies are available on the impact of reduced indoor air 
pollution on either low birth weight or preterm birth.
Stillbirth
Studies on the impact of indoor air pollution on stillbirths 
are restricted to South Asian countries. Mavalankar, in 
India, found a nonsigniﬁ  cant increase in stillbirth risk in 
a case control study among women exposed to smoke 
(OR 1.5; 95% CI 1.0–2.1)[26]. Another population-based 
Indian study showed that women using biomass fuels had 
a signiﬁ  cantly higher risk of stillbirth than those utilizing 
cleaner fuels (OR 1.44; 95% CI 1.04–1.97)[27]. Siddiqui et 
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of stillbirths in pregnant women exposed to biomass fuel 
(OR 1.90; 95% CI 1.10–3.20)[28].
Assessment
Th   ere is a lack of studies relating indoor air pollution to 
preterm birth, especially randomized controlled trials 
[29, 30]. Th   erefore the quality of evidence is very low and 
the recommendation is weak against the intervention for 
this particular outcome. For low birth weight and 
stillbirths, the quality of the evidence is low, as it is largely 
based on observational studies. However, the inter-
vention is strongly recommended for the prevention of 
respiratory infections [31, 32]. Future studies of measures 
to reduce indoor air pollution must also measure 
pregnancy and neonatal outcomes.
Interventions given during pregnancy
Smoking cessation programs
More than 80% of all smokers now reside in low- and 
middle-income countries, with an estimated prevalence 
of 49% among men and 8% among women [33, 34]. 
Recent prevalence studies of smoking during pregnancy 
also show wide variability, [35] with rates above 25% in 
South America [36], 8% in urban Africa [37] and 18% in 
the Paciﬁ  c Islands [38].
Mechanisms that increase the risks of preterm birth 
and stillbirth among smokers are not clear. It is known, 
however, that both nicotine and carbon monoxide are 
potent vasoconstrictors, produce placental damage, and 
decrease the uteroplacental blood ﬂ  ow [39].
Preterm birth
Cigarette smoking is a well-known cause of preterm birth 
and intrauterine growth restriction [40]. In a Cochrane 
review published in 2004, smoking cessation inter  ventions 
signiﬁ  cantly reduced low birth weight (RR 0.81; 0.70–0.94) 
and preterm birth (RR 0.84; 0.72–0.98), as well as smoking 
during pregnancy [41]. It should be noted, however, that 
the experience of smoking cessation programs is 
predominantly from high-income countries [42].
Stillbirth
Notwithstanding the established beneﬁ  ts to mother and 
fetus, there are few studies that have reported the eﬀ  ect 
of smoking cessation on perinatal outcomes and 
stillbirths. One cohort study from Sweden shows 
increased risk of stillbirths among smokers [43].
Assessment
Th   e quality of evidence is high for both preterm birth and 
low birth weight, and the intervention has a strong 
recommendation, especially in countries where smoking 
has a high prevalence during pregnancy. Th  e strong 
recommendation is reinforced by other well-known 
eﬀ   ects of smoking on health. Th  e lack of studies on 
smoking cessation and stillbirth outcomes points to a 
data gap that should be ﬁ   lled. Maternal exposure to 
second-hand smoke is an additional research gap. It 
should also be noted that all studies reviewed originate 
from high-income settings, and therefore intervention 
studies in low- and middle-income settings are needed.
Balanced protein energy supplementation
Maternal undernutrition is still a major problem in the 
world’s poor countries [44]. Energy intake in pregnancy is 
positively associated with fetal growth [40]. In popula-
tions with food insecurity and high rates of maternal 
under  nutrition, balanced energy protein supplemen  t-
ation—including up to 25% of the total energy content in 
the form of protein—may improve fetal growth and 
reduce the risk of fetal and neonatal death.
Preterm birth
A Cochrane review of seven trials of balanced protein 
energy supplementation for pregnant women did not 
show a signiﬁ  cant  eﬀ   ect on preterm births (RR 0.83; 
0.65–1.06), but intrauterine growth restriction was 
reduced by 32% (RR 0.68; 0.54–0.86) [45]. Five of the 
seven trials were carried out in LMICs.
Stillbirth
Th  e same review showed a signiﬁ  cant reduction in the 
risks of stillbirth (RR 0.55; 95% CI 0.31–0.97) and a near-
signiﬁ  cant reduction in neonatal deaths (RR 0.62; 95% CI 
0.37–1.05) [45].
Assessment
Th   e quality of evidence is high and the intervention is not 
recommended for preventing preterm birth. However, 
this intervention is strongly recommended in appropriate 
populations (food insecure households and mothers with 
low body mass index) due to its aﬀ  ect on fetal growth and 
on preventing stillbirth.
Multiple micronutrient supplementation
Low serum levels of micronutrients such as iron, folate 
and zinc, are highly prevalent among pregnant women 
in low-income settings, and are associated with preterm 
birth and stillbirth [44, 46-48]. Undernourished 
pregnant women consume less vitamins and minerals in 
their diets and have reduced blood volume and 
decreased uterine blood ﬂ  ow [49]. As a consequence, 
diﬀ  erent nutritional interventions have been tried for 
women at high risk of nutritional deﬁ  ciencies, including 
supplements of speciﬁ  c micronutrients, such as zinc, 
iron and folate, magnesium and calcium, given either 
singly or in combination.
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A review of nine RCTs comparing multiple micronutrient 
supplementation during pregnancy with either no 
supplements, two or fewer micronutrients, or placebo, 
showed a reduction in low birth weight (RR 0.84; 95% CI 
0.74–0.95), IUGR (RR 0.92; 95% CI 0.86–0.99) and 
maternal anemia (RR 0.61; 0.52–0.71), but no eﬀ  ect on 
preterm birth [50]. A more recent trial in Tanzania 
compared multivitamins with placebo; the intervention 
group showed a reduction in low birth weight (RR 0.82; 
95% CI 0.70–0.95) and in the frequency of small for 
gestational age newborns (RR 0.77; 95% CI 0.68–0.87), 
but no eﬀ  ect on preterm births or fetal mortality [51].
A 2006 meta-analyses of multiple micronutrient supple-
mentation compared with iron and folic acid found no 
diﬀ  erences in maternal or neonatal outcomes [50]. However, 
when a 2008 RCT from Indonesia [52] was added to this 
meta-analysis, a signiﬁ  cant reduction in low birth weight 
was observed (OR 0.84; 95% CI 0.74–0.95) [53].
Stillbirth
A reasonably large number of studies have recently 
evaluated the impact of multiple micronutrients on 
perinatal mortality and stillbirth outcomes. A recent 
meta-analysis was conducted, including trials published 
since the most recent Cochrane reviews, of the impact of 
multiple micronutrient supplementation in pregnancy 
[54]. Th  e meta-analysis (nine RCTs, N=40,222 women, 
N=20,277 intervention group, N=19,945 controls) com-
pared the impact on stillbirths of multiple micronutrient 
supplementation during pregnancy (intervention) with 
either iron or iron and folate (controls) and found a 
nonsigniﬁ   cant trend toward reduced stillbirths among 
the intervention group versus the control group (RR 0.91, 
95% CI: 0.80-1.03).
One note of caution was provided by the report of 
increased birth asphyxia among babies in the inter-
vention group in two micronutrient supplemen  tation 
RCTs carried out in Nepal [55-57]. Th   eir pooled analysis 
showed increased rates of perinatal and neonatal 
mortality (RR 1.52; 95% CI 1.03–2.25) in the intervention 
group. However, such an eﬀ   ect was not found in the 
Indonesia randomized trial, where infant mortality was 
18% lower among infants whose mothers were supple-
mented with micronutrients [52]. In sites where these 
RCTs were carried out, most births took place either at 
home or in health posts, with limited access to emergency 
obstetric care. In Indonesia however, the study area had 
trained midwives and a signifcnatly greater proportion of 
births were assisted by skilled birth attendants. Th  us  this 
intervention must be viewed in the context of health 
system functionality and might provide beneﬁ  ts  in 
circumstances where skilled care and facility births are 
available [58].
Assessment
Th  ere is high quality evidence the intervention has a 
signiﬁ  cant impact on low birth weight but no eﬀ  ect on 
preterm births or stillbirths. However, due to moderate-
quality evidence of increased neonatal mortality in 
South Asia, more information is necessary from 
eﬀ  ectiveness trials in diﬀ  erent health systems settings 
before the intervention can be recommended for scaling 
up.
Iron and folate supplementation
Iron and folate are key elements for red cell production 
and iron-deﬁ  ciency anemia, the most common nutrient 
deﬁ  ciency among pregnant women. Routine iron or iron-
folate supplementation is recommended for correcting 
anemia during pregnancy [59].
Preterm birth
A meta-analysis of four trials of iron supplementation 
during pregnancy, with and without folic acid, [60] 
showed a reduction in anemia but no signiﬁ  cant eﬀ  ect on 
preterm birth (RR 0.76; 95% CI 0.47–1.24) or low birth 
weight (RR 0.59; 95% CI 0.23–1.49).
Stillbirth
Th   e impact of iron or iron-folate supplementation on the 
prevention of stillbirth is mixed, [54] partly because most 
studies are underpowered to detect diﬀ  erences.  Th  e 
Cochrane review by Pena-Rosas et al. on antenatal iron 
supplementation found a nonsigniﬁ  cant risk of increased 
perinatal mortality with iron supplementation compared 
to placebo (RR 2.50, 95% CI 0.10–59.88)[60]. Another 
study from Th   e Gambia, reported stillbirth rates of 2.9% 
vs. 4.3% in intervention (200 mg oral ferrous sulphate) 
and control groups, respectively [61].
Assessment
Th  ere is moderate evidence of a lack of eﬀ  ect for iron-
folate supplementation on preterm birth, low birthweight 
and stillbirth. Although this is based on randomized 
trials, the quality of the evidence is moderate, because 
the conﬁ  dence intervals are very wide. Th  e recommen-
dation—based exclusively on these outcomes—is weak 
against supplementation. Nevertheless, the well known 
impact of iron and folate in the prevention of maternal 
anemia result in a strong recommendation in favor of 
supplementation.
Zinc supplementation
Zinc plays an important role in many biological func-
tions, including protein synthesis and nucleic acid meta-
bo  lism [62]. Mild to moderate zinc deﬁ  ciency is common 
in low-income settings, where pregnant women tend to con-
sume less than the recommended daily intake of 15 mg [63].
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In a Cochrane review of 13 trials, seven of which were 
from low-middle income countries, zinc supplementation 
during pregnancy led to a modest reduction of 14% (95% 
CI 0.76–0.98) in preterm birth, but had no eﬀ  ect on low 
birth weight (RR 1.05, 95% CI 0.94–1.17), suggesting this 
eﬀ  ect may be restricted to large preterm babies [64] .
Stillbirth
Th   e recent Cochrane review of 9000 pregnancies 
mentioned above had 7 studies that reported no eﬀ  ects 
on stillbirth and perinatal mortality outcomes. Th  e  single 
study [55] undertaken in Nepal, a population with low 
maternal zinc status, reported no eﬀ  ect on stillbirths or 
other perinatal deaths (RR 1.03, 95% CI 0.71–1.51). A 
recent review of the subject [65] also did not report any 
stillbirth or other perinatal outcomes [55].
Assessment
Th  e quality of evidence for zinc supplementation on 
stillbirth, preterm birth and low birth weight is high. Th  e 
intervention is not recommended for the prevention of 
low birth weight or stillbirths, and has a weak recom-
mendation for preventing preterm births, given its small 
eﬀ  ect size. No ﬁ  rm conclusion was reached on the eﬀ  ect 
of maternal zinc supplementation on stillbirth.
Magnesium sulfate supplementation
Magnesium sulfate reduces uterine contractility both in 
vivo and in vitro, indicating this intervention may prevent 
preterm birth and stillbirth [66].
Preterm birth
A meta-analysis of seven intervention trials with oral mag-
nesium treatment starting before the 25th week of gestation 
showed a lower frequency of preterm birth (RR 0.73, 95% CI 
0.57–0.94), as well as a reduction in low birth weight (RR 
0.67, 95% CI 0.46 to 0.96) and improved maternal outcomes 
(hemorrhage and hospital admissions). However, authors of 
the Cochrane review noted that the studies included in the 
review had important shortcomings [67].
Stillbirth
Th   e Cochrane review [67] included three RCTs with 1954 
recipients that reported stillbirth outcomes and showed 
no impact (RR 1.0, 95% CI 0.29–3.44).
Assessment
Th  e quality of evidence is moderate for both preterm 
birth and low birth weight, and there is a weak recom-
mendation against the intervention until better studies 
become available. Th   ere is fairly consistent evidence that 
magnesium has no impact on stillbirth, and the recom-
mendation is strong against the intervention for this 
outcome. A recent Cochrane review shows a reduced risk 
of cerebral palsy in the oﬀ  spring of high-risk women who 
received magnesium sulfate [68] and thus this 
intervention should be evaluated further with a range of 
alternative outcomes.
Calcium supplementation
It is estimated that hypertension complicates 5% of all 
pregnancies and 11% of ﬁ  rst pregnancies, accounting for 
nearly 40,000 maternal deaths annually [69]. Due to the 
known inverse association between calcium intake 
during pregnancy and hypertension, [70], supplementa-
tion has been tried in a number of studies.
Preterm birth
Calcium supplementation trials in low-risk women in 
populations with low-calcium diets reduced the risk of 
preeclampsia (RR 0.48; 95% CI 0.33–0.69) but its impact 
on preterm birth (10 trials, RR 0.81; 95% CI 0.64–1.03) 
and low birth weight (8 trials, RR 0.84, 95% CI 0.68–1.03) 
was not quite signiﬁ  cant [71]. However, when the analysis 
was restricted to the four small studies including 568 
women at high risk of preeclampsia, there was a 
signiﬁ  cant decrease in preterm birth (RR 0.45, 95% CI 
0.24 to 0.83).
In a recent small placebo-controlled RCT in low-risk 
Indian primigravidae with low dietary calcium, calcium 
supplementation led to less preeclampsia (OR 0.31; 95% 
CI 0.15–0.63) and signiﬁ  cantly fewer preterm births (OR 
0.51; 95% CI 0.28–0.93)[72].
Stillbirth
Th   e Cochrane review [71] reported stillbirth and neonatal 
death before discharge in 10 trials with 15,141 participants, 
but showed no impact (RR 0.89, 95% CI 0.79–1.09).
Assessment
Th   e quality of evidence for preterm birth and low birth 
weight is moderate, and the intervention has a weak 
recom  mendation for preventing preterm birth. For 
stillbirth, the quality of evidence is high suggesting a 
lack of eﬀ  ect.  Th   erefore, the intervention is not 
recommended for these particular outcomes. However, 
it is strongly recommended for preventing preeclampsia 
in populations with low levels of dietary intake of 
calcium.
Supplementation with long-chain polyunsaturated fatty acids
Long-chain polyunsaturated fatty acids (LCPUFA) are 
precursors to the 3-series prostaglandins, which 
modulate inﬂ  ammatory and vascular eﬀ  ects [73]. Because 
hypertension during pregnancy and preeclampsia are 
associated with vasoconstriction and endothelial damage, 
it is postulated these fatty acids play a beneﬁ  cial role.
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Five randomized trials found that marine oil supple-
mentation to low-risk women did not show any eﬀ  ect on 
preterm births (RR 0.92, 95% CI 0.79, 1.07), low birth 
weight, or the risk of preeclampsia [74]. Two RCTs 
showed LCPUFA supplementation was associated with a 
signiﬁ  cantly lower rate of early preterm birth (<34 weeks 
of gestation) (RR 0.39, 95 % CI 0.18, 0.84)[75].
Stillbirth
No reported outcomes.
Assessment
Th   e quality of evidence is high showing no eﬀ  ect of the 
intervention to prevent preterm birth and low birth 
weight. Th   e recommendation against the intervention is 
strong for these outcomes given the current state of 
evidence. Further studies are needed on a possible eﬀ  ect 
on early preterm birth.
Cardiotocographic monitoring
One Cochrane review and two observational studies 
testing the impact of antepartum cardiotocography 
(including both NST and CST) on perinatal outcomes 
were identiﬁ  ed [76-78]. Th   e Cochrane review by Pattison 
& McCowan [76] included four studies (N=1,588 preg-
nancies) of the impact of cardiotocography use on 
perinatal mortality in high- or intermediate-risk preg-
nancies. Th  e trial reported a trend toward increased 
perinatal mortality in the cardiotocography group versus 
controls receiving no monitoring or whose cardioto  co-
graphy results were concealed from the clinician; (3 trials, 
N=1279 pregnancies, OR 2.85, 95% CI: 0.99–7.12). 
However, the studies were underpowered to assess such 
an impact. Th  e observational studies do indicate a 
correlation between non-reassuring cardiotocographic 
traces and adverse perinatal outcomes, including still-
birth. While there are few RCTs evaluating the impact of 
cardiotocographic monitoring on reducing stillbirth, 
apparent reductions in stillbirth rates have followed the 
incorporation of the stress testing and cardiotocographic 
monitoring into protocols for management of high-risk 
pregnancy in the United States. Fetal arousal tests such as 
vibroacoustic stimulation have largely been evaluated in 
high-income countries. Th   ere is a need for further studies 
in LMICs with limited CTG facilities [79].
Assessment
Th   ere are surprisingly few studies evaluating the relation-
ship of cardiotocographic monitoring with stillbirth and 
the overall quality of available evidence is low. In light of 
the probable link with improved outcomes in developed 
countries, and the widespread use of low-cost CTG 
monitoring equipment in clinical practice, the current 
recommendation is weak. Further studies must be con-
ducted with appropriate design and power to assess this 
intervention in health systems in developing countries.
Doppler and late ultrasound monitoring
Doppler ultrasound is a technique to study the feto-
placental and/or uteroplacental circulatory dynamics. A 
Cochrane review included 11 RCTs comparing umbilical 
artery Doppler ultrasound in complicated pregnancies 
with no Doppler, and found a nonsigniﬁ  cant  21% 
reduction in the stillbirth rate (OR 0.79, 95% CI 0.46–
1.34) [80]. A similar review of late ultrasound examina-
tion for all pregnancies – whether or not these were 
complicated – showed no eﬀ  ect [81].
Assessment
Th   ere is high-quality evidence suggesting a lack of eﬀ  ect 
on stillbirth, and the recommendation against this inter-
vention is strong.
Interventions for pregnancy infections
Screening and treatment of syphilis
Syphilis during pregnancy is common in many LMICs, 
with prevalence in local studies varying widely from less 
than 1% to 10% or higher [82]. African studies show 
prevalence during pregnancy of 3.4% in Uganda, [83] 
7.7% in Tanzania,[84] 12% in Malawi, and 17.4% in 
Cameroon [85]; [86]. Syphilis produces villitis and 
obliterative arteritis, which are severe lesions in the 
placenta associated with fetal and newborn mortality [87].
Preterm birth
During pregnancy, observational studies show associa  tions 
between syphilis and both preterm birth and low birth 
weight. In Tanzania, women with high-titer active syphilis 
had a six-fold greater risk of preterm birth and a three-fold 
increase in low birth weight compared with seronegative 
women. It was estimated that syphilis accounts for one 
fourth of the preterm births in this population [88]. An 
earlier study from Malawi also found an increase of 
preterm and low birth weight babies among women with 
syphilis (OR 3.6; 95% CI 1.6-7.9) [89]. All studies reviewed 
are from LMICs.
Penicillin eﬀ  ectively reduces the risk of congenital syphilis 
[84, 90], but there are no intervention studies showing an 
eﬀ  ect of syphilis screening and treatment on preterm birth.
Stillbirth
Th  e eﬀ   ectiveness of antibiotics in curing gestational 
syphilis and preventing congenital infection was 
established in the 1940s, before RCTs had been adopted 
[90]. Observational studies in Swaziland, and Kenya 
suggest syphilis screening and treatment is associated 
with reduced perinatal mortality [91] and reduced 
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propor  tion of stillbirths was higher among women 
treated for low-titer active syphilis (4.8%) vs. seronegative 
women (2.5%) (crude OR = 1.95, 95% CI: 0.96 – 4.0); 
being similar for women treated for high-titer active 
syphilis (2.3%) versus seronegative ones (2.5%). For 
ethical reasons it was not possible to have an untreated 
group with syphilis, but these results suggest that 
treatment of high-titer women can reduce the risk. Th  e 
results for low-titer women are diﬃ   cult to interpret in 
the absence of an untreated comparison group.
Assessment
Th   e quality of evidence for preventing preterm birth, low 
birth weight and stillbirth is moderate, being based on 
observational studies and accumulated knowledge. Given 
the current level of knowledge, it is not expected that 
RCTs will be conducted as these would be unethical. Th  e 
recommendation is weak in favor of the intervention for 
preventing preterm birth or low birth weight. Th  e 
recommendation is strong in favor of recognizing and 
treating maternal syphilis to reduce stillbirth and 
congenital syphilis.
Intermittent presumptive treatment during pregnancy (IPTp) 
(for malaria)
Malaria is a key cause of maternal illness and anemia in 
pregnancy, especially among primiparae in areas where 
malaria is endemic such as sub-Saharan Africa and parts 
of Latin America and Asia. Malaria prevention includes 
the use of antimalarial drugs administered presumptively 
through strategies such as intermittent preventive 
treatment during pregnancy (IPTp) and the use of 
insecticide-treated bed nets (ITNs).
Preterm birth
Malaria infection may aﬀ  ect fetal growth and gestational 
duration through maternal anemia and placental 
infection [93]. A systematic review of interventions with 
antimalarials during pregnancy showed that – among 
women in their ﬁ  rst or second pregnancies - treatment 
reduced anemia, parasitaemia, placental malaria, 
perinatal deaths and low birth weight (six trials, RR 0.57; 
95% CI 0.46-0.72). No eﬀ   ect on preterm births was 
observed in the only trial assessing this outcome [94].
Stillbirth
A Cochrane review on prophylactic antimalarials or IPTp 
showed no overall eﬀ  ect, but when the analyses were 
restricted to women in their ﬁ  rst or second pregnancy, 
antimalarials signiﬁ   cantly reduced perinatal mortality 
(RR 0.73; 95% CI 0.53–0.99) and were associated with a 
smaller, nonsigniﬁ  cant reduction in stillbirths (RR 0.87; 
95% CI 0.62–1.21) [94].
Assessment
Although there is little evidence for preterm birth or 
stillbirth, the quality of evidence is high for using IPTp to 
reduce low birth weight and perinatal mortality in malaria-
endemic areas. IPTp is thus strongly recommended for 
women in their ﬁ  rst or second pregnancy.
Insecticide-treated mosquito nets (ITNs)
ITNs are known to decrease malaria transmission and 
reduce mortality [95]. Nevertheless, it is estimated that 
only a small fraction of women and children living in 
malarious areas are currently protected [96].
Preterm birth
A review of ﬁ  ve randomized clinical trials of ITNs during 
pregnancy—four in Africa and one in Th  ailand—showed 
a 33% reduction in low birth weight in the African trials, 
but no eﬀ   ect in Th  ailand [97]. In the only trial with 
information on preterm births, conducted in Kenya [98], 
no eﬀ  ect was demonstrated.
Stillbirth
Th  e same Cochrane review showed a 33% reduction in 
fetal losses (abortions and stillbirths) in the ﬁ  rst to fourth 
pregnancy (RR 0.67; 95% CI 0.47–0.97), but not in ﬁ  fth 
and higher-order pregnancies [97, 99].
Assessment
Th   e quality of evidence is high for low birth weight and 
stillbirth, and the intervention is strongly recommended 
for these outcomes. Th  ere is very limited evidence—a 
single RCT—for preventing preterm birth, and the 
recom  mendation is weak (against), given that this trial 
found no eﬀ  ect. Overall, ITNs are strongly recommended 
due to their eﬀ  ect on maternal and child mortality and 
morbidity. Th  ere are few studies employing a combina-
tion of IPTp and ITN on pregnancy outcomes, including 
preterm birth and stillbirth.
Screening and treatment of asymptomatic bacteriuria
Genital and urinary infections, including asymptomatic 
bacteriuria,  may aﬀ   ect preterm birth. One possible 
pathway could be a direct intrauterine infection, but it is 
also possible that the infection produces an inﬂ  ammatory 
reaction that leads to preterm birth, even after the 
infection has been treated [39].
Preterm birth
Observational studies show an association between 
maternal urinary tract infections and both preterm birth 
and low birth weight. A meta-analysis of four observa-
tional studies indicated a decreased risk of preterm birth 
(RR 0.51, 95% CI 0.36-0.69) in nonbacteriuric pregnant 
women in comparison to those with bacteriuria [100].
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the effect of antibiotics versus placebo [101] on 
different outcomes. Treatment reduced maternal 
pyelonephritis (RR 0.23; 95% CI 0.13-0.41) and low 
birth weight (7 studies; RR 0.66; 95% CI 0.49-0.89), but 
did not signifi  cantly reduce preterm birth (3 studies; 
OR 0.37; 95% CI 0.10-1.36). The three studies 
addressing preterm birth, however, had a number of 
methodological problems, such as using different cut-
off points (<38 weeks in two studies and <37 weeks in 
one), having small sample sizes, and different 
diagnostic and treatment criteria.
Stillbirth
No reported outcomes.
Assessment
Th   e quality of evidence for preterm birth is low, but it is 
high for low birth weight. Th  e intervention is strongly 
recommended for preventing low birth weight and 
reducing maternal morbidity, but has a weak recommen-
dation for preventing preterm births. Further studies are 
required on preterm birth and stillbirth.
Screening and treatment of bacterial vaginosis
As is the case for bacteriuria, bacterial vaginosis might 
contribute to preterm labor through infectious or 
inﬂ  ammatory mechanisms [39]. Pregnant women with 
bacterial vaginosis are two to three times more likely to 
have a preterm birth than women without vaginosis [39]. 
It is not clear, however, whether this is a causal associa-
tion [102].
Preterm birth
Several systematic reviews of screening and treatment for 
bacterial vaginosis found no impact on preterm births or 
low birth weight [103-108]. Because of this, routine 
pregnancy screening and treatment of bacterial vaginosis 
is not recommended [109-111].
However, RCTs in which antibiotics were given before 
20 weeks found a signiﬁ  cant reduction in preterm births 
(RR 0.72; 95% CI 0.55-0.95) [107]—but further trials are 
needed before a recommendation for early treatment can 
be issued. It is possible the bacteria that cause the 
infection may ascend into the uterus before or during 
early pregnancy, starting an inﬂ  ammatory response that 
would not be aﬀ  ected by late treatment [39].
Stillbirth
No reported outcomes.
Assessment
Th   ere is high quality evidence the treatment of bacterial 
vaginosis has a lack of eﬀ  ect for preventing preterm 
birth or low birth weight. A strong recommendation is 
made against the use of the intervention. Th  e  eﬀ  ect of 
early treatment of bacterial vaginosis on preterm birth 
and stillbirth is a research gap that needs to be 
addressed.
Prevention of mother-to-child transmission of HIV
In high-income countries, highly active antiretroviral 
therapy (HAART) has markedly reduced vertical trans-
mission rates of HIV. However, there is concern that 
preterm rates may have increased among treated women. 
Analyses have yielded inconsistent results with respect to 
pregnancy outcomes. In particular, it is uncertain 
whether or not combination ART—most speciﬁ  cally that 
which includes protease inhibitors (PI’s)—is associated 
with an increase in preterm births.
Preterm birth
Observational studies, particularly those from Europe, 
report increased rates of preterm birth in women 
receiving HAART during pregnancy. Th  is risk was 
particularly pronounced for PI use that started early in 
pregnancy or before conception. For example, a multi-
center European collaborative study including nearly four 
thousand mothers reported relative risks of preterm birth 
of 2.60 (95% CI 1.43-4.75) and 1.82 (95% CI 1.13-2.92), 
for those exposed to combination therapy with and 
without a protease inhibitors, respectively, compared to 
no treatment [112]. An observational study in the USA 
also showed increased rates of preterm birth among 
women receiving HAART with protease inhibitors, 
compared with any other treatment option (OR 1.8; 95% 
CI 1.1-3.0)[113]. However, a 2007 meta-analysis of 1 
retrospective and 13 prospective studies, including the 
aforementioned, showed that antiretroviral therapy 
during pregnancy is not associated with an overall 
increased risk of preterm birth [114]. Th  e use of 
combination regimens before or early in pregnancy may 
slightly increase the risk of preterm birth, although 
confounders such as maternal HIV-stage may contribute 
to this observation. Observational studies suggest an 
association between preterm birth and use of HAART in 
pregnancy, in particular initiating PI-based HAART early 
in gestation, but inadequately control for stage of 
maternal HIV disease and other potential confounding 
variables [115-118].
Stillbirth
Fewer studies report on stillbirth outcomes and anti-
retroviral therapy during pregnancy. A report combining 
two completed clinical trials and ﬁ  ve  ongoing, 
prospective observational studies from the United States 
found similar rates of stillbirths between women who did 
and did not receive antiretroviral therapy during 
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included observational studies continued to show either 
no association between ART and stillbirth [113] or a 
decreased risk for stillbirth (OR 0.06, 95% CI 0.02-0.18)
[120]. Townsend et al., 2007 compared women on 
HAART with women on mono/dual therapy. In 
comparison with exposure to mono/dual therapy, 
exposure to HAART was associated with a nonsigniﬁ  cant 
increased risk of stillbirth (adj. OR=2.27, 95% CI: 0.96-
5.41; p=0.063)[121].
Finally, there was no signiﬁ  cant diﬀ  erence in stillbirth 
rates between groups of women treated with HAART 
throughout pregnancy and short-course therapy in the 
two studies originating from low-income countries [122, 
123].
Assessment
Th  e use of combination antiretroviral therapy has 
dramatically decreased the rate of maternal-to-child 
HIV transmission. However, observational data suggest 
a possible association between ART therapy and 
increased risk of preterm birth. Th   is may be particularly 
burdensome in low-income countries, particularly those 
with less access to neonatal care. Large-scale, 
randomized, controlled trials are needed to deﬁ  ne the 
risk of HAART therapy and adverse pregnancy 
outcomes.
Anti-helminthic treatment
Hookworm infestation is associated with anemia in 
women and children in endemic areas. In such areas, 
routine antenatal mebendazole therapy could greatly 
reduce the prevalence of anemia in pregnancy.
Preterm birth
One RCT in Peru found no diﬀ  erence in low birth weight 
between women receiving anti-helminthitic therapy 
(mebendazole) compared to placebo (8.1% and 8.7%, 
respectively; p=0.7). Both groups received iron 
supplements. No information on gestational age was 
available [124]. A recent Cochrane review of the 
treatment of soil-related helminths in pregnancy shows 
no statistically signiﬁ  cant impact on preterm birth (RR 
0.85, 95% CI 0.38-1.87) or low birth weight (RR 0.94, 95% 
CI 0.61-1.42) [125].
Stillbirth
An observational study from Sri Lanka on the eﬀ  ect of 
mebendazole therapy during pregnancy on birth 
outcomes showed that stillbirths and perinatal deaths 
combined were signiﬁ  cantly less common among women 
who received mebendazole as part of antenatal care (RR 
0.55; 95% CI 0.4–0.77) [126]. However, the Peruvian RCT 
did not show statistically signiﬁ  cant diﬀ  erences in rates 
of miscarriage, stillbirth (8/522 in the mebendazole plus 
iron group vs. 4/520 in placebo plus iron) or early 
neonatal death [127], but was underpowered for these 
outcomes.
Assessment
Th   e quality of evidence is low, and there is a weak recom-
mendation against using anti-helminthics to prevent 
stillbirth. Very little information is available on preterm 
birth. Hookworm treatment, however, is recom  mended 
for pregnant women to reduce anemia in high-prevalence 
populations.
Screening and treatment for periodontal disease
Periodontal disease has been associated with preterm 
birth, but the biological pathway for this association is 
not known. One possible explanation may be gingival 
infection resulting in intrauterine infection, via maternal 
bacteraemia and transplacental passage. Th  is  relationship 
is not proven [39].
Preterm birth
A meta-analysis of observational studies indicate asso-
ciations between periodontal disease and preterm birth 
[128], but clinical trials show conﬂ  icting results [129]. 
From the four available RCTs, two showed no eﬀ  ect of 
treatment on preterm birth or low birth weight [130]. 
Th  e other two described reductions in preterm birth, 
and one RCT showed a reduction in low birth weight 
[131, 132].
Stillbirth
No reported outcomes.
Assessment
Although RCTs on the impact of periodontal treatment 
on preterm birth or low birth weight are available, the 
quality of the evidence is moderate, because results so far 
are inconclusive. Currently, the intervention is not 
recommended for the sole intent of preventing preterm 
birth or low birth weight. Th  e intervention may be 
beneﬁ  cial for improving maternal oral health, but further 
research on fetal outcomes is needed.
Interventions for pregnancies with high-risks of preterm 
birth or stillbirth
Progesterone
Progesterone has been proposed for preventing the 
recurrence of preterm birth. Th  e possible mechanisms 
supporting its use include: anti-inﬂ  ammatory  action, 
oxytocin antagonism (producing relaxation of smooth 
muscle), maintenance of cervical integrity, and reduced 
gap-junction formation [109].
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A meta-analysis of six randomized trials comparing the 
use of progesterone with placebo in high-risk women, 
showed a reduction of preterm births in the intervention 
group (RR 0.65, 95% CI 0.54-0.79)[133], as well as a 
decreased prevalence of low birth weight (four studies, 
RR 0.63, 95% CI 0.49-0.81). Five of the six trials are from 
high-income settings.
Stillbirth
Th  e same meta-analysis failed to show a signiﬁ  cant 
impact on perinatal deaths (ﬁ  ve studies, RR 0.66; 95% CI 
0.37-1.19).
Assessment
Th   e evidence of progesterone use to prevent recurrence 
of preterm birth is high and the intervention is strongly 
recommended. For stillbirth, the evidence is moderate 
due to the wide conﬁ   dence interval, and the 
recommendation is weak against this intervention.
Cervical cerclage
Cervical cerclage is used for the treatment of an 
incompetent cervix that is associated with previous 
spontaneous abortion or miscarriage.
Preterm birth
In four RCTs of cervical cerclage for high-risk women, 
reviewed in a Cochrane publication [134], there was no 
diﬀ  erence in the occurrence of preterm births between 
intervention and control women (RR 1.04, 95% CI 
0.99–1.10).
Stillbirth
Another Cochrane review showed a nonsigniﬁ  cant 20% 
reduction in perinatal loss, death at or after 24 weeks of 
gestation and up to the ﬁ  rst week of neonatal life. (RR 
0.80, 95% CI 0.48–1.36) [135]. A more recent systematic 
review of seven RCTs also found similar results for 
pregnancy loss or death before hospital discharge (OR 
0.81, 95% CI 0.60–1.10) [136].
Assessment
Th   e quality of evidence is high for both preterm birth and 
pregnancy loss. Th  e recommendation is strong against 
the intervention for preventing preterm delivery, and 
weak against for preventing stillbirth, due to greater 
uncertainty in the evidence.
Multivitamins for HIV+ women
Poor maternal micronutrient status has been associated 
with faster clinical and immunological evolution of HIV 
disease. Th  is association led to research on vitamin 
supplementation [137].
Preterm birth
A systematic review of four RCTs comparing the use of 
vitamin A with placebo in HIV-positive pregnant women 
did not show signiﬁ  cant eﬀ  ects on maternal-to-child HIV 
transmission (OR 1.06; 95% CI 0.89-1.26) or preterm 
birth (RR 0.88, 95% CI 0.65–1.19). Th  e intervention 
signiﬁ  cantly increased mean birth weight by 89 g (95% CI 
85-95) and resulted in a near-signiﬁ  cant reduction in low 
birth weight (RR 0.83, 95% CI 0.68-1.01) [138].
Stillbirth
Only one study reported fetal loss (miscarriage and 
stillbirth) and indicated a reduction in stillbirth with multi-
vitamin supplementation among HIV-infected women in 
pregnancy (30/512 in supplemented groups versus 49/509 
in controls (RR 0.61, 95% CI 0.39-0.94)[137].
Assessment
Th   e quality of evidence for preterm birth and low birth 
weight is moderate due to uncertainty in the estimates, 
whereas the quality is low for stillbirth given that only 
one study is available. Th  e recommendation is weak 
against this intervention.
Intrapartum interventions to prevent stillbirth
Intrapartum deaths account for a third of all stillbirths 
globally. Interventions to reduce such deaths include 
acting on the demand side by helping families seek care 
from skilled attendants, and acting on the supply side by 
improving access to and the quality of skilled care. Th  ese 
interventions are reviewed in terms of their potential 
impact on stillbirth and other perinatal outcomes, as 
intrapartum procedures are not carried out with the 
objective of aﬀ  ecting preterm birth.
Birth preparedness
Birth preparedness consists of preparing the mother, 
family and community for delivery and potential 
complications. It includes several measures such as 
seeking appropriate care during pregnancy, identifying 
the place of delivery, acquisition of sterile materials and 
planning for skilled birth attendance and referral if 
needed—including setting aside money and arranging for 
transportation to a facility [139].
In recent years many community based trials in Asia have 
employed various cadres of community health workers and 
support groups to promote birth prepared  ness and eﬀ  ective 
newborn care [140-143]. Such community-based inter-
ventions can play an important role in promoting birth 
preparedness, especially in seeking emergency obstetric 
care. However, existing studies include birth preparedness 
as part of a package of several other antenatal and delivery 
interventions, so it is not possible to separate the impact of 
birth preparedness alone.
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Th  ere is high quality evidence that community-based 
interventions that include birth preparedness can prevent 
stillbirths. However, the eﬀ  ects of birth preparedness per 
se cannot be assessed. Community-based interventions 
are strongly recommended in appropriate settings where 
the proportion of home deliveries is high.
Use of partogram
A partogram, also called a partograph, is a simple pre-
printed paper form on which midwives and obstetricians 
can record the progress of labor. Th  e tool provides a 
continuous pictorial overview of the progress of labor, 
and distinguishes between the latent and active phases of 
labor. Slower progress identiﬁ  ed by the alert line on the 
partograph can be used as a basis for transfer to a facility 
for skilled intervention and delivery.
Th   e recent Cochrane review by Lavender et al. 2008 [144] 
showed no statistically signiﬁ  cant eﬀ  ect of partogram use on 
the Caesarean section rate (RR 0.64, 95% CI: 0.24–1.70), 
instrumental vaginal delivery (RR 1.00, 95% CI: 0.85–1.17) 
or Apgar score <7 at 5 minutes (RR 0.77, 95% CI: 0.29 – 
2.06). Th  ere was no perinatal mortality in the two groups 
(partograph with 2-hour action line vs. 4-hour action line) 
in studies in high-resource settings [145, 146] included in 
this review. A large, multicenter study from Southeast Asia 
[147] reported a stillbirth rate of 0.3% among women using 
the partogram vs. 0.5% for the control group.
Assessment
Th  e quality of evidence reviewed for evaluating the 
partogram for care during delivery is low, given the 
controlled circumstances in which these studies have 
been conducted. Th   e recommendation is weak in favor of 
this intervention. Further RCTs are required in which 
stillbirth is a primary outcome.
Fetal movement monitoring
Reduced fetal movements are associated with a higher 
risk of stillbirth, [148] and fetal movement records or 
kick charts have been proposed as a screening 
mechanism. However, a large RCT comparing the impact 
of the use of kick charts on unexplained stillbirths found 
no diﬀ   erence in the rate of fetal death between the 
intervention (2.9/1000) and control group (2.7/1000) 
[149]. Another study comparing fetal monitoring with 
hormonal proﬁ  ling in 1191 pregnant women [150] was 
inconclusive (RR 3.19, 95% CI 0.13-78.2).
Assessment
Only two studies are available on this intervention, both 
from developed countries, with no signiﬁ  cant  eﬀ  ects  on 
stillbirth. As a consequence, the quality of the evidence is low 
and there is a strong recommendation against its adoption.
Emergency obstetric care
Many intrapartum stillbirths can be prevented with 
improved obstetric care, including emergency cesarean 
sections (c-sections). It is estimated that no fewer than 
5% of all deliveries require a c-section due to maternal or 
fetal indicators [151, 152]. Th   ese operations gained wide 
acceptance several decades ago, and therefore 
randomized trials are not available regarding their overall 
eﬀ  ect on stillbirths. Ecological analyses using countries as 
the data units show that, in low and middle-income 
countries, each one percentage point increase in the 
c-section rate is associated with a reduction of 1.6/1,000 
in the intrapartum stillbirth rate; this is observed for 
c-section rates between 0 and 8%, after which the 
relationship ﬂ  attened out [153].
Instrumental deliveries using forceps or vacuum 
extraction account for 5 – 20% of all births in most high-
income countries [154]. As is the case for c-sections, 
there are no RCTs of instrumental versus non-instru-
mental approaches for complicated deliveries, but trials 
comparing diﬀ  erent types of instruments are available. A 
Cochrane review of seven RCTs comparing vacuum 
versus forceps reported a nonsigniﬁ  cant  diﬀ  erence  in 
perinatal mortality rate in the two methods (OR 0.80; 
95% CI 0.18–3.52), with extremely wide conﬁ  dence limits 
[155]. Other studies also reported similar neonatal 
outcomes in the two groups [156]; [157].
Assessment
Th   e quality of evidence in favor of c-sections or instru-
mental deliveries, compared to no such procedures, is 
moderate for stillbirths. Fifteen of the 40 studies reviewed 
on this topic were carried out in LMICs. RCTs for testing 
these approaches would be unethical. Th  e recom  men-
dation is strong in favor of the interventions to prevent 
stillbirths. Excessively high c-section rates, however, 
should be avoided, as the frequency of preterm delivery 
and neonatal mortality both rise at rates of caesarean 
delivery of between 10% and 20% [158].
Cesarean section for breech presentation
Around 3-4% of term singleton pregnancies are compli-
cated by breech presentation. A total of six studies were 
identiﬁ   ed, three of which were from LMICs. A 
Cochrane review of three RCTs comparing planned 
cesarean with planned vaginal delivery for breech 
infants showed a 71% reduction in perinatal or neonatal 
death, excluding fatal malformations (RR 0.29; 95% CI 
0.10-0.86) [159].
Assessment
Th   e quality of evidence for preventing perinatal mortality 
is high and the recommendation for this intervention is 
strong.
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Induction of labor is advocated when vaginal delivery is 
the appropriate route of delivery and gestational age is 41 
completed weeks or more. Th  e Cochrane review com-
paring induction with expectant management consisting 
of twelve trials in low-risk women with intact membranes 
showed a nonsigniﬁ  cant reduction in stillbirths (RR 0.28; 
95% CI 0.05–1.67) and a signiﬁ  cant impact on perinatal 
mortality (RR 0.30; 95% CI 0.09–0.99)[160]. Only one of 
the 15 studies identiﬁ  ed, which included controlled trials 
and observational studies, was from an LMIC.
Assessment
Th  e quality of evidence for elective induction for post-
term pregnancies is high for perinatal mortality, and the 
recommendation is strong in favor of the intervention in 
low-risk pregnant women at 41 weeks or more.
Elective induction for women with term premature rupture of 
membranes (PROM)
Another Cochrane review summarized the eﬀ  ect  of 
induction in women with term, premature rupture of 
membranes. Th  e pooled results of ﬁ  ve RCTs suggest a 
reduction in fetal or perinatal mortality (OR 0.46; 95% CI 
0.13–1.66)[161]. No stillbirth outcomes were reported 
separately. Although this diﬀ   erence is not signiﬁ  cant, 
there were signiﬁ  cant improvements in other maternal 
and infant morbidity indicators.
Assessment
Th   e quality of evidence for perinatal mortality is 
moderate given the wide uncertainty of the estimates, 
and the recommendation is weak in favor of induction. 
However, the recommendation is strong for improving 
other maternal and infant outcomes.
Home delivery versus facility births
Mothers in low- and, to a lesser extent, middle-income 
countries often do not have a choice about where to 
deliver their babies due to limited access to hospital care. 
Th  e evidence from RCTs of home versus institutional 
birth is therefore derived from high-income countries. A 
Cochrane review [162] found a near-signiﬁ  cant increase 
in risk of perinatal mortality (ﬁ  ve trials; RR 1.83; 95% CI 
0.99-3.38) in home-like settings, compared to hospital 
deliveries. In Australia, an observational study [163] 
reported a signiﬁ  cant reduction in perinatal mortality in 
delivering at ‘alongside hospital’ birth centers compared 
to hospital deliveries, but these results may have been 
aﬀ  ected by selection bias.
Assessment
Th   e quality of evidence for perinatal mortality is moderate, 
and the recommendation is weak against home delivery.
Intrapartum interventions to improve preterm survival
Th   is section reviews interventions for the mother when 
preterm labor has been initiated but the newborn has not 
yet been delivered. Th   e main objective of these 
interventions is to improve the survival of preterm 
newborns.
Prophylactic corticosteroid therapy in preterm labor
Several agencies recommend that women in preterm 
labor before 34 weeks and those with preterm rupture of 
membranes (PROM) under 32 weeks should receive a 
single dose of either betamethasone or dexamethasone 
[164-166]. A Cochrane review showed use of cortico-
steroids in preterm labor reduced respiratory distress 
syndrome by 36% (RR 0.64, 95% CI 0.56-0.72), with a 
maximum eﬀ  ect at 32 weeks of gestation. Steroids also 
reduced cerebral hemorrhage by 70% (RR 0.30; 95% CI 
0.14-0.66), and neonatal mortality by 37% (RR 0.63; 95% 
CI 0.51-0.77) [167]. Four of the 21 studies reviewed are 
from LMICs.
Assessment
Th  e quality of evidence for preventing preterm birth, 
morbidity and mortality is high and the intervention is 
strongly recommended.
Antibiotics for preterm labor with premature rupture of 
membranes (PROM)
Premature rupture of membranes is strongly associated 
with infection of the amniotic membranes, and this 
infection is independently related to preterm birth, [168] 
cerebral palsy and chronic lung disease [169]. A Cochrane 
review showed antibiotic treatment for PROM led to 
reductions in the proportion of babies born within 48 
hours (RR 0.71; 95% CI 0.58-0.87), and reduced neonatal 
infections (RR 0.68; 95% CI 0.53-0.87), surfactant use (RR 
0.83; 95% CI 0.72-0.96), oxygen therapy (RR 0.88; 95% CI 
0.81-0.96), and abnormal cerebral ultrasound scans prior 
to hospital discharge (RR 0.82; 95% CI 0.68-0.98) [170]. 
No diﬀ  erences in long-term follow-up were observed in 
the babies of intervention and control groups [171]. Five 
of the 22 studies reviewed are from LMICs.
Assessment
Th  e quality of evidence on morbidity and mortality is 
high and the intervention is strongly recommended to be 
scaled up to improve preterm survival.
Antibiotics for preterm labor with intact membranes
Meta-analyses of RCTs of the use of antibiotics for 
preterm labor with intact membranes did not show 
improvements in preterm birth or in preterm morbidity 
(RR 1.03; 95% CI 0.86-1.24) [172, 173]. In addition, in a 
seven year follow-up study, increased functional 
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received erythromycin during labor [174].
Assessment
Th  e quality of evidence is high, and there is a strong 
recommendation against antibiotics for preterm labor 
with intact membranes.
Early versus delayed cord clamping in preterm newborns
Immediate umbilical cord clamping, often within 
15 seconds after delivery, is the current practice in most 
settings. A limited number of observational trials, most 
of which were conducted prior to 1980 [175-180] have 
given way to this belief. Th   ese trials reported higher rates 
of complications in preterm newborns with delayed cord 
clamping [181].
Two recent meta-analyses of outcomes among preterm 
newborns [182, 183] have challenged the beneﬁ  t  of 
immediate cord clamping. Beneﬁ   ts of delayed cord 
clamping included higher circulating blood volume 
during the ﬁ   rst 24 hours of life, less need for blood 
transfusions and lower incidence of intraventricular 
hemorrhage (RR= 0.53, 95% CI= 0.35 - 0.79). Th  ere  was 
also no signiﬁ   cant increase in the risk of respiratory 
distress syndrome (RR= 0.83, 95% CI= 0.59 - 1.15) or 
necrotizing enterocolitis (RR= 2.08, 95% CI= 0.52 - 8.37). 
Early cord clamping was associated with a nonsigniﬁ  cant 
increased mortality risk in babies compared to delayed 
clamping (RR1.40, 95% CI 0.59-3.32, p=0.45).
Four recent additional RCTs [184-187] were identiﬁ  ed 
out of which only one study [186] reported relevant 
outcomes, showing no diﬀ   erences in mortality rates 
(p=1.00), intraventricular hemorrhage (p=0.67) or 
necrotizing enterocolitis (p=1.00) between the early and 
delayed cord clamping groups.
Assessment
On the basis of available evidence, a 30-second delay in 
cord clamping is a safe intervention for preterm 
newborns. Th  e quality of the evidence is high and the 
recommendation is strong in favor of this intervention. 
All studies are from high-income countries.
Postnatal interventions to improve preterm survival
Th  is section reviews interventions aimed at improving 
the management of preterm newborns to reduce neonatal 
mortality.
Neonatal resuscitation
About 5-10% of newborns require some form of resusci-
ta  tion ranging from simple maneuvers to assisted venti-
latory support [188]. Resuscitation is a diﬃ   cult  inter-
vention to review given the obvious constraints in study 
design and locations. Given the paucity of data and 
limited studies in preterm newborns, we have also 
included relevant summary information from studies 
undertaken among term newborns and have summarized 
the information from preterm newborns, where available. 
Th  e ﬁ   nal recommendations are thus based on the 
biological plausibility and feasibility of the intervention.
Th  e literature reviews four main areas of research 
regarding resuscitation:
1. Modes of oxygen delivery and resuscitation techniques
Diﬀ  erent approaches have been used for oxygen delivery 
to the neonate (face mask, bag mask, nasal cannulae, 
CPAP) and these may vary in terms of achieving adequate 
oxygen saturation and hence dictate the need for further 
management (intubations, CPR etc). Only one study 
addressed preterm neonates exclusively [189] while 
others reported outcomes in all newborns.
Capasso et al [190] compared oxygen delivery on inter-
mittent positive pressure with nasal cannulae versus 
facial mask in primary resuscitation of the newborn with 
moderate asphyxia, concluding that while resuscitation 
with nasal cannulae required fewer intubations and chest 
compressions, it had comparable survival rates and 
Apgar scores to normal controls. Palme et al [191] 
compared the eﬃ   ciency of ﬁ  ve widely used face masks on 
newborns with respect to the rates of leakage and 
frequency and ease of cleaning. Th  ey reported least 
leakage with circular silicone rubber mask (‘Laerdal’) and 
found it easier to clean, boil and autoclave.
Massawe et al [192] found that mouth-to-mask and 
bag-to-mask ventilation were comparable in terms of 
Apgar scores, heart rate and time to ﬁ  rst breath. Th  e  only 
RCT on preterm newborns [189] evaluated the impact of 
nasal CPAP on BPD and the need for intubation, 
reporting a lower number of intubations in neonates 
given nasal CPAP on admission to the NICU compared 
to those who were not given nCPAP.
Th   ese results suggest that nasal CPAP is preferable to 
manual inﬂ  ations in preterm newborns and may lower 
the need for chest compressions and intubations, whereas 
mouth-to-mask ventilation is equivalent to bag-to-mask 
ventilation for neonates. Th  e American Academy of 
Pediatrics has initiated a Helping Baby’s Breathe program 
(AAP, personal communication 2009) to enable lower 
level health workers to undertake standardized 
resuscitation in primary care settings. Validation studies 
of the protocol are underway.
Assessment
As for CPR, while guidelines for resuscitating preterm 
newborns exist there are a number of areas of uncertainty 
which require further research and reﬁ  nement. On the 
basis of moderate-quality evidence, it appears that bag 
and mask resuscitation is adequate in most circumstances. 
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adequacy of this form of resuscitation in community 
settings in well designed, large scale studies.
2. Use of cardio-pulmonary resuscitation (CPR) techniques and its 
long- and short-term outcomes
Th   e crucial role of neonatal resuscitation in immediate 
newborn care is well accepted [193]. On the other hand, 
its use has also been associated with adverse long- and 
short-term outcomes possibly due to survival of severely 
aﬀ  ected newborns [194-196]. Given that RCTs of such 
interventions are diﬃ   cult, we reviewed seven observa-
tional studies from PubMed and one interventional 
study from Cochrane clinical trials. Segregated data for 
term and preterm neonates was available for two 
studies, whereas other authors did not separate these 
two groups.
Vakrilova et al [197] discussed the need of delivery 
room cardio-pulmonary resuscitation (CPR) in VLBW 
and ELBW neonates and reported that birth weight and 
gestational age are the most important factors, deter-
mining the intensity of delivery room CPR and the 
prognosis in newborns of < 1500 g. Multiple studies 
reported the long-term outcomes including language 
symmetry, attention shift, visual attention, neuropsycho-
logical sequela and social and educational adjustments. 
While language symmetry and attention shift [196] were 
impaired in the individuals given CPR at birth, there was 
no diﬀ  erence between the resuscitated and non resusci-
tated groups in terms of other parameters for long-term 
outcomes [195, 196, 198, 199]. Dorfsman et al [200] 
compared two thumb technique of neonatal CPR versus 
American Heart Association recommended two ﬁ  nger 
tech  nique. He reported that TT (two thumb) chest 
compression produced higher MAP, systolic and diastolic 
blood pressures when compared with TF (two ﬁ  nger) 
chest compression technique during a clinically relevant 
duration of prolonged CPR.
Sanchez-Torres et al [194] evaluated the impact of CPR 
provided in delivery room on survival and short term 
neurological outcomes in preterm infants. Th  e infants 
receiving CPR and those infants who did not were 
comparable in terms of mortality, NEC, IVH and BPD. 
However the infants undergoing CPR needed surfactant 
and oxygen more frequently. On the other hand Deulofeut 
et al [201] reported higher rates of mortality, IVH and 
periventricular leucomalacia in neonates who were 
provided CPR at birth.
Assessment
While it is entirely appropriate to resuscitate preterm 
newborns, there are a number of issues that require 
further research as the current quality of the evidence is 
low. Th  ese include appropriate techniques and duration 
for CPR in preterm newborns and understanding 
intermediate- and long-term outcomes.
3. Room air (versus 100% oxygen) for resuscitation
Th  e optimum oxygen concentration required for new-
born resuscitation has been the subject of investigation 
[202]. While 100% oxygen has been traditionally used for 
all cyanotic infants [203], reports of increasing incidence 
of hypoxic ischemic encephalopathy (HIE), as well as 
other secondary outcomes, have made its use debatable. 
High oxygen levels were also associated with adverse 
outcomes like high oxidative stress [204] and increased 
incidence of leukemia [205].
It has been proposed that room air is as eﬀ  ective as 
100% oxygen in overcoming neonatal asphyxia, [188] and 
several studies and systematic reviews addressed this 
issue [202, 203, 206]; [188, 204, 207-210].
Th  ree intervention studies on preterm infants [211-
213], all from high-income settings, reported similar 
mortality and morbidity rates, including BPD, among 
those resuscitated with room air or 100% oxygen (p=0.95 
for NMR) [211], p=0.71 for NMR [212].
Studies which did not separate term and preterm 
newborns compared 100% oxygen with room air, 
concluding either that outcomes are similar in both 
groups, or that the room air group has advantages in 
terms of morbidity and mortality [202, 203, 206]. Saugstad 
et al [214] also reported no diﬀ  erences in neurodevelop-
mental outcomes between neonates resuscitated with 
room or 100% oxygen and this ﬁ  nding has been replicated 
in a recent population based study by Hellstrom-Westas 
et al. [215].
Assessment
Th   ese studies indicate the use of room air is comparable 
to 100% oxygen with respect to primary neonatal 
outcomes with some ostensible beneﬁ  ts.  Th  e overall 
quality of evidence is high and this intervention can be 
recommended as a standard approach to resuscitating 
preterm neonates.
4. Provision of facilities and training health professionals in 
neonatal resuscitation
Many studies conﬁ  rm that training programs for neonatal 
resuscitation are vital for survival [193, 216, 217].
Impact on preterm infants was observed in three 
studies where training programs led to signiﬁ  cant reduc-
tions in terms of mortality and morbidity [218, 219, 220]. 
Specialized neonatal resuscitation teams have also played 
an important role in reducing preterm neonatal 
morbidity and mortality [221].
Additional studies, mostly observational, document the 
impact of training programs on all newborns, either term 
or preterm. Th   ere is ample documentation on the impact 
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technical abilities of health professionals, and on 
reducing neonatal morbidity and mortality rates [219, 
222-239]. Similar outcomes were also observed by the 
employment of specialized neonatal resuscitation teams 
[221, 240, 241].
Finally, large-scale studies support the eﬀ  ectiveness of 
resuscitation programs. Sen et al [217] demonstrated a 
21% reduction in mortality after a sick newborn care unit 
was set up in Kolkata that included resuscitation 
facilities. Enweronu-Laryea et al [242] reported similar 
eﬀ  ect of improved neonatal care facilities on neonatal 
survival in Ghana which provided improved obstetric 
services, referral systems, well developed neonatal units 
and trained staﬀ  .
Assessment
While speciﬁ   c data on the beneﬁ   t of resuscitation 
training programs on survival of preterm infants is 
limited, it is plausible that adequately trained health 
professionals and neonatal resuscitation programes are 
also eﬀ   ective in reducing asphyxia-related preterm 
mortality as well as reducing complications such as 
neurodevelopmental delay, NEC and BPD. Given the 
large number of observational studies carried out under 
diverse settings, the quality of the evidence is judged to 
be moderate. Th   is intervention is recommended with the 
provision that these outcomes be evaluated in large-scale 
eﬀ  ectiveness settings.
Vitamin A supplementation in preterm neonates
Vitamin A is involved in the growth and diﬀ  erentiation of 
various body cells including those of the respiratory, 
gastrointestinal and immune systems. Preterm infants 
are deﬁ   cient in vitamin A due to inadequate hepatic 
stores and the inability to tolerate routine oral supple-
mentation [243, 244].
A 2007 Cochrane review of very low birth weight 
infants showed a signiﬁ  cant but small reduction in death 
or oxygen use at one month [RR= 0.93; 95% CI 0.88, 0.99] 
in infants receiving intravenous vitamin A compared to 
placebo [243]. Th   ere were also nonsigniﬁ  cant reductions 
in nosocomial infection and neurodevelopmental delays 
at 18 to 36 months of age.
Th   e recent Lancet Nutrition series identiﬁ  ed neonatal 
vitamin A supplementation in South Asia were associated 
with a signiﬁ  cant reduction in infant mortality at 6 months 
[245]. From these recent trials of neonatal vitamin A 
supplementation, it was possible to obtain separate data 
for preterm infants from three RCTs [246-248]. and to 
conduct an additional meta-analysis. Neonatal vitamin A 
supplementation among preterm infants was associated 
with a nonsigniﬁ  cant reduction in infant mortality at 6 
months of age (RR 0.87; 95% CI 0.65, 1.17).
Assessment
Th  e quality of evidence is moderate given the small 
number of studies including preterm infants and the 
uncertainty in estimates. WHO has recently commis-
sioned three large prospective RCTs in community 
settings to evaluate the impact of neonatal Vitamin A 
supplementation. Given current knowledge, there is a 
weak recommendation against its use in preterm infants, 
but this may well change as the evidence accumulates.
Antenatal and postnatal vitamin K supplementation in 
preterm infants
Vitamin K is a fat-soluble vitamin crucial to the produc-
tion of many proteins involved with the coagula  tion 
process. Since 1961 the Committee on Nutrition of the 
American Academy of Pediatrics has recommended that 
prophylactic vitamin K be administered parenterally to 
all newborns, primarily for preventing intracranial 
hemor rhage  [249].
Vitamin K treatment of pregnant mothers before 
preterm delivery has also been proposed. A Cochrane 
review [250] evaluated ﬁ  ve randomized or quasi-random-
ized trials of vitamin K administered parenterally or 
orally to women at risk of imminent preterm birth, none 
of which were from LMICs. Th   e primary outcomes were 
neonatal mortality, neonatal neurological morbidity, as 
measured by the presence of periventricular haemorrhage 
(PVH) on ultrasound during the ﬁ  rst week of life, and 
long-term neurodevelopment. Antenatal vitamin K was 
associated with a nonsigniﬁ  cant reduction in all grades of 
PVH (RR 0.82, 95% conﬁ  dence interval (CI) 0.67-1.00) 
and in severe PVH (grades 3 and 4) (RR 0.75, 95% CI 
0.45-1.25) for babies receiving prenatal vitamin K 
compared with control babies. In a subsequent RCT by 
Liu et al [251], 90 pregnant women in preterm labor at 
less than 35 weeks of gestation received vitamin K1 
10 mg per day injection intramuscularly or intravenously 
for 2-7 days, or no such treatment. Th  e overall rates of 
PVH were 32 and 52%, respectively (p=0.036), and the 
frequency of severe PVH was 5 and 20%, respectively 
(p=0.038). Although the quality of the trials is variable 
and further studies are needed, these data suggest a 
possible role for antenatal maternal vitamin K 
administration as a means of reducing risks of PVH and 
mortality in preterm infants.
Evidence supporting the use of injectable vitamin K 
(phytomenadione) shortly after birth to prevent 
hemorrhage-related morbidity and mortality was accu-
mu  lated before RCTs were widely adopted, being based 
on observational studies. Th  e strongest evidence from 
high-income countries comes from periods in which 
concerns about the safety of vitamin K led to its reduced 
use in newborns; these periods were followed by 
increased incidence of hemorrhagic disorders [252].
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preterm infants remain uncertain. Due to ethical reasons 
recent RCTs did not include a placebo group, but 
compared diﬀ  erent treatment modes, using vitamin K 
status as the primary outcome. [253, 254].
Assessment
Th  e quality of the evidence for both antenatal and 
postnatal vitamin K use is moderate. Th  ere is a strong 
recommendation for postnatal vitamin K, and a weak 
recommendation in favor of antenatal vitamin K for 
women in premature labor.
Postnatal zinc supplementation in preterm infants
Zinc plays an important role in growth and immune 
function [255]. Zinc is the second most important micro-
nutrient deﬁ   ciency in infants after Iron [256]. Zinc 
deﬁ   ciency has been reported to aﬀ   ect the growth of 
infants, especially those born preterm or small for gesta-
tional age [257].
Six studies addressed postnatal zinc supplementation 
in infants who were small at birth, but four of these 
apparently excluded preterm newborns and were not 
included in the present review [258-261].
One study [262] looked at postnatal zinc supplemen-
tation in very low birth weight infants (<1500 g), most of 
whom are likely preterm. Th  ere was a positive eﬀ  ect of 
supplementation on length gain, but not for weight or 
head circumference. Th  ere was also a positive eﬀ  ect on 
locomotor development.
A second study [263] assessed zinc supplementation in 
low birth weight infants (<2500 g) in a community based 
randomized controlled trial. Th  e authors found that 
postnatal zinc supplementation is eﬀ  ective in reducing 
incidence of diarrheal episodes and helps in linear growth 
and weight gain in infants born with low birth weight.
Assessment
Notwithstanding the interesting ﬁ  ndings in these studies, 
the overall quality of the evidence is low regarding the 
beneﬁ  t of zinc supplementation in preterm infants, and 
there is a weak recommendation against the intervention 
until further studies with adequate samples and 
gestational age assessment are available.
Postnatal selenium supplementation
Selenium is involved in the human immune system and 
its deﬁ  ciency can lead to impaired immunity [264, 265].
A Cochrane review comprising three RCTs, [266] 
assessed the eﬀ  ect of postnatal selenium supplementation 
on mortality and morbidity in preterm infants. Selenium 
was associated with a reduction in one or more episodes 
of sepsis after seven days [RR= 0.73 (0.57, 0.93)]. 
However, no signiﬁ  cant diﬀ  erence was seen in rates of 
mortality or oxygen use. Th  ere was a nonsigniﬁ  cant 
reduction in retinopathy of prematurity (any grade) 
among supplemented infants. Th   e review concluded that 
postnatal selenium supplementation potentially reduced 
episodes of late onset neonatal sepsis but did not improve 
survival rates.
Assessment
While some experts have recommended selenium 
supple  mentation of preterm formulas (Klein 2002), the 
quality of the evidence is moderate due to the small 
number of studies, and there is a weak recommendation 
in favor of supplementation. Further studies are urgently 
needed.
Chlorhexidine treatment on the cord
Of the 4 million annual neonatal deaths, approximately 
36% are attributable to infections [267] with the cord as a 
common portal of entry for organisms. Th   e use of topical 
cord antiseptics has been proposed as a potential 
preventive measure [268]. Chlorhexidine appears to be 
particularly useful because of its wide-ranging activity 
against Gram-positive and Gram-negative bacteria [269], 
and the fact that it can be applied to the umbilical stump 
of the newborn as well as used for skin wiping and 
washing.
We identiﬁ  ed two RCTs on the use of chlorhexidine on 
the umbilical stump. Th  e  ﬁ  rst was restricted to preterm 
infants with gestational age <34 weeks and birth weight 
<2500g [270], while the other included both term and 
preterm infants [271]. Th   e Pezzati trial compared 
chlorhexidine to salicylic sugar powder for umbilical cord 
care in preterm infants in neonatal care units, showing 
that the incidence of bacterial colonization was lower 
with salicylic group compared to chlorhexidine. Th  ere 
were no deaths in this trial, nor was there a control group 
with traditional cord care.
In Nepal, a community based trial showed that 
chlorhexidine use was associated with a 24% nonsigniﬁ  -
cant reduction (95% CI 0.55-1.04) in neonatal mortality 
compared to dry cord-care; among infants enrolled within 
the ﬁ  rst 24 hours, mortality was signiﬁ  cantly lower in the 
intervention group (RR 0.66; 95% CI 0.46-0.95) [271].
Chlorhexidine can also be used to cleanse the skin of the 
newborn. A recent large community-based RCT trial in 
rural Nepal [272] included 17,000 term and preterm infants. 
Th   e intervention did not signiﬁ  cantly aﬀ  ect mortality rates 
in term infants. However, a statistically signiﬁ  cant reduction 
(28%) in mortality rates among low birth weight infants was 
documented (RR= 0.72, 95% CI= 0.55-0.95).
Assessment
Despite the interesting ﬁ  ndings from these studies, the 
overall evidence for the beneﬁ   ts of chlorhexidine use 
Barros et al. BMC Pregnancy and Childbirth 2010, 10(Suppl 1):S3 
http://www.biomedcentral.com/1471-2393/10/S1/S3
Page 22 of 36among preterm infants is moderate and further trials are 
needed to validate impact before recommending this 
intervention for widespread use.
Community case management of sepsis and pneumonia in 
preterm neonates
Th   e World Health Organization recommends parenteral 
antibiotic therapy in a health facility as the standard 
treatment for serious neonatal infections (i.e., septicemia, 
pneumonia, and meningitis) in LMICs [273]. However, 
this may not be the most feasible approach in low-income 
countries and alternative strategies may be needed [193]. 
Community case-management with antibiotics of 
neonatal sepsis and pneumonia has shown promising 
results [274]. Th   e present review has examined the eﬀ  ect 
of this approach on the survival of sick preterm neonates.
Early studies of community management of neonatal 
sepsis did not include a suﬃ   cient number of preterm 
newborns for separate analyses [275]. In a similar study 
Datta et al [276] undertook a prospective controlled 
study of the case management of ARI in low birth weight 
infants, but did not distinguish preterm infants. Th  ey 
found a 64% reduction in case fatality due to ARI in the 
intervention area as compared to the control population, 
as well as declines of 24% (95% CI 6%-35%) in the infant 
mortality rates and 58% in the pneumonia speciﬁ  c 
mortality rates.
Th   e study of home-based newborn care by Bang et al. 
[233] conducted in rural India found that case fatality in 
preterm neonates declined by 69.5 % (from 33.3 to 10.2%, 
p<0.0001). Case fatality in preterm low birth weight 
neonates without sepsis who received only supportive 
care decreased from 28.2 to 11.5% (p<0.01), and among 
those with sepsis who received supportive care and 
antibiotics decreased from 61% to 13.2% (p<0.005).
Assessment
Available data on community-based case management of 
neonatal sepsis and pneumonia in LMICs make a 
compelling case for providing such care in circumstances 
where referral may not be possible. While the overall 
evidence is moderate due to the small number of studies 
reporting on results among preterm infants, additional 
evidence is provided by studies including newborns in 
general, whether term or preterm. Th  ere is a strong 
recommendation in favor of this intervention in 
appropriate settings.
Kangaroo mother care (KMC)
Th   e kangaroo mother care (KMC) method was developed 
in the 1970´s in Colombia in response to overcrowded 
neonatal care units [277]. Th  is method includes three 
main components: 1) skin-to-skin contact—a newborn 
baby is kept in a prone position between the mother’s 
breasts several hours a day; 2) exclusive on-demand 
breastfeeding; and 3) early hospital discharge with 
appropriate follow-up. KMC is aimed at low birth weight 
babies, usually born preterm. It is applied after these 
babies are stabilized in terms of temperature, respiratory 
function and feeding [278]. Th   e method has been recently 
adapted to non-hospital settings [279].
A systematic review carried out in 2003 [278] was 
updated to incorporate recent trials [279-281]. Four 
RCTs associated KMC with a reduction in severe 
morbidity (pooled RR 0.51; 95% CI 0.37-0.70). Five 
hospital-based studies reporting on neonatal mortality of 
infants under 2000 g, showed a pooled RR of 0.64 (95% 
CI 0.43-0.94). A community-based RCT in Bangladesh 
showed a signiﬁ  cant reduction in neonatal mortality (RR 
0.37; 95% CI 0.16-0.86) when analyses were restricted to 
newborns weighing 2000 g or less, but the diﬀ  erence in 
infant mortality was not quite signiﬁ  cant (RR 0.56; 95% 
CI 0.30-1.05). It should be noted that 40% of the infants 
in this trial did not have a birth weight measure, so this 
latter analyses should be interpreted with caution. All 
studies are from LMICs.
Assessment
Th   ere is a high level of evidence that hospital-based KMC 
is an eﬀ  ective method of preventing severe morbidity and 
mortality, especially in low- and middle-income 
countries. Th  e intervention is inexpensive and feasible, 
and therefore strongly recommended for hospital 
settings.
On the other hand, the evidence on community-based 
KMC is restricted to a single study with less clear results. 
In addition, that study failed to reach compliance with 
the recommended practice, which raises issues about its 
feasibility for widespread implementation [279]. New 
research is needed on the best ways to scale up the 
intervention at a community level and for estimating its 
impact on morbidity and mortality.
Early breastfeeding
Breastfeeding has many beneﬁ  cial  eﬀ  ects,  including 
protection against neonatal morbidity and mortality, 
[282-284] and long-term improvements in cognitive 
function [285, 286].
Th   e composition of breast milk changes during the ﬁ  rst 
week of life. Colostrum intake is particularly important 
due to its many antimicrobial properties [287]. Early 
breastfeeding ensures the infant’s intake of colostrum is 
maximized, and also promotes the establishment of 
lactation by stimulating prolactin production.
Th   e timely initiation of breastfeeding in the ﬁ  rst hour 
of life is promoted by international organizations, such as 
UNICEF and WHO [288]. For preterm newborns, most 
of whom are unable to suckle until 34 weeks of gestational 
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using a cup and spoon to administer expressed milk.
Th   ere is ample evidence from RCTs that early skin-to-
skin contact, as in kangaroo mother care, increases the 
duration of total and exclusive breastfeeding [278, 280, 
291, 292]. Because early breastfeeding is associated with 
exclusive and total breastfeeding duration, and the latter 
with reduced morbidity and mortality, it is reasonable to 
expect that early breastfeeding will reduce these poor 
outcomes. However, only two observational studies 
conducted in Ghana and Nepal evaluated the eﬀ  ect of 
early breastfeeding on neonatal mortality, both showing 
that delayed initiation was associated with higher 
neonatal mortality [293, 294]. A third study from Egypt 
also reported increased diarrhea incidence in the ﬁ  rst six 
months of life among babies who were put to the breast 
three or more days after birth [295].
Th  e literature comparing breast milk against formula 
feeding in early life is more abundant than that 
comparing early versus late breastfeeding initiation. A 
recent systematic review [284] found two RCTs and three 
cohort studies, all showing signiﬁ  cant protective eﬀ  ects 
of human milk on systemic infections and necrotizing 
enterocolitis. A separate 2003 meta-analysis of four RCTs 
showed preterm babies receiving human milk were less 
likely to develop necrotizing enterocolitis (RR 0.34; 95% 
CI 0.12-0.99) than infants who received formula milk 
[283]. When a more recent study was added to this meta-
analysis, [296] the pooled RR was equal to 0.28 (95% CI 
0.11-0.69).
Assessment
Th  ere is a high quality of evidence that breast milk has 
beneﬁ  cial  eﬀ   ects in the prevention of necrotizing 
enterocolitis and severe infections in preterm babies. On 
the other hand, the level of evidence of an association 
between early breastfeeding and neonatal mortality is 
only moderate. Th   e intervention is strongly 
recommended to be scaled-up due to its multiple 
beneﬁ  ts.
Thermal care immediately after birth
Th  e normal body temperature of a newborn baby is 
between 36.5 and 37.5°C, and hypothermia refers to body 
temperature below 36.5°C [297]. Hypothermia is a danger 
sign in preterm babies, [298] and it has long been known 
that preventing heat losses in these babies improves 
survival [299]. Preterm babies are highly susceptible to 
hypothermia due to their low body fat, and this condition 
is highly prevalent in low- income countries [300-302].
A “warm chain” to prevent hypothermia in the 
newborn child includes 10 steps: 1) warm delivery room; 
2) immediate drying; 3) skin-to-skin contact; 4) breast-
feeding; 5) bathing and weighing postponed; 6) appropriate 
clothing/bedding; 7) mother and baby together; 8) warm 
transportation; 9) warm resuscitation; and 10) training 
and awareness raising [297]. Other methods to keep the 
baby’s temperature include radiant heaters, polyurethane 
bags, cling ﬁ   lms, thermal mattresses, incubators, and 
topical application of oil or paraﬃ   n-based  ointments 
[303, 304].
Because RCTs of thermal care versus no thermal care 
would not be ethical, available studies compare diﬀ  erent 
methods. A Cochrane review [305] concluded use of 
plastic wraps or bags, transwarmer mattresses, and early 
skin-to-skin contact, all kept preterm and/or low birth 
weight babies warmer compared to routine thermal care. 
Another Cochrane review compared incubators with 
radiant heaters in preterm babies [306], showing no 
diﬀ   erences in severe infections or deaths, although 
radiant heaters were associated with greater water loss.
Two of these interventions—use of plastic wraps and 
early skin-to-skin contact—are particularly relevant for 
LMICs, and were subjected to new meta-analyses. Th  ree 
studies of skin-to-skin contact [280, 307, 308] in low 
birth weight children were located, and the pooled RR of 
hypothermia was signiﬁ   cantly lower in infants in the 
skin-to-skin group compared to those receiving routine 
care (0.13; 0.07-0.24). Th  ree trials [309-311] and one 
observational study [312] assessed mortality impact in 
preterm babies, all with small sample sizes. Th  e overall 
RR was 0.62 (95% CI 0.35-1.10). Th  ese four studies 
showed signiﬁ  cant improvements in thermal control, as 
did another Indian trial for which mortality was not 
reported [313].
In addition, two recent community trials of essential 
newborn care packages showed hypothermia control can 
be feasibly scaled-up for home deliveries [314]; [315]. 
One of these compared a package including traditional 
skin-to-skin thermal care with a package including 
Th  ermoSpot, which is a liquid crystal sticker that 
indicates hypothermia by changing color. Hypothermia 
recognition and thermal care increased in both groups, 
but the Th   ermoSpot package did not show an advantage 
over the package of essential newborn care.
Th  ree of the seven studies included in the two meta-
analyses were from LMICs.
Assessment
Th  e quality of the evidence supporting thermal control 
relative to absence of control is based on observational 
studies carried out in the distant past, and according to 
the GRADE guidelines is judged as moderate – even 
though RCTs would be unethical. Several diﬀ  erent 
approaches were shown to provide adequate thermal 
control in RCTs. Of particular relevance to LMICs are 
skin-to-skin contact and plastic wraps, both of which are 
superior to routine thermal care in terms of keeping 
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Comparisons of skin-to-skin contact relative to routine 
care suggest a possible impact on mortality, but the 
conﬁ  dence interval is wide. Th   e overall recommendation 
for skin-to-skin contact and plastic wraps is strong.
Application of continuous distending pressure to the lung for 
respiratory distress syndrome (RDS)
Continuous distending pressure (CDP) to the lung 
includes applying positive pressure via the nose or 
trachea or negative pressure around the chest, and is 
used to treat respiratory distress syndrome (RDS). In the 
absence of surfactant replacement therapy, CDP to the 
lung reduces the need for intubation and mechanical 
ventilation (pooled RR 0.72; 95% CI 0.56-0.91) and 
decreases the composite outcome of death or respiratory 
failure (pooled RR 0.65; 95% CI 0.52-0.81) [316]. 
However, CDP may increase the risk of pneumothorax 
(pooled RR 2.64; 95% CI 1.39-5.04). Compared to late 
administration, early CDP results in a lower use of 
intubation and mechanical ventilation (RR 0.55; 95% CI 
0.32-0.96) [317].
Nasal CPAP refers to the application of CDP to the 
lungs via prongs placed in the nose and is a valid 
alternative to routine intubation and mechanical ventila-
tion in treating RDS [318-324]. In a systematic review 
comparing prophylactic nCPAP to standard therapy 
among very preterm infants (<32 weeks or <1500 g) that 
included two studies, no signiﬁ  cant diﬀ  erences in rates of 
intubation, bronchopulmonary dysplasia, mortality, 
pneumo  thoraces or other morbidities were noted [325].
Nasal CPAP may be particularly useful in low-resource 
settings. In Fiji, a pre-evaluation and post-evaluation 
showed a 50% reduction in the need for mechanical 
ventilation among newborns with RDS after introduction 
of nCPAP [326]. A small non-randomized study in South 
Africa found nCPAP reduced mortality by 50% compared 
with oxygen alone for preterm newborns between 26 to 
28 weeks gestation with RDS [327].
Even in the surfactant era, a multicenter trial of 610 
infants between 25 and 28 weeks gestation randomized 
to either nCPAP or intubation and mechanical ventilation 
within 5 minutes of birth found no diﬀ  erences in the 
primary outcome of BPD or death [328], but fewer 
infants who received CPAP required oxygen at 28 days 
after birth. Pneumothorax was more frequent in the 
nCPAP group perhaps because they did not receive early 
surfactant.
Nasal CPAP is best delivered using bi-nasal prongs 
while the end expiratory pressure is generated by placing 
the expiratory limb of a constant ﬂ  ow circuit into water 
at a depth suﬃ   cient to generate the required pressure 
(bubble CPAP) [329-331]. Other methods are more 
expensive and may not be more eﬀ  ective [331-333].
Assessment
Th  e quality of evidence of nCPAP for treatment of 
respiratory failure among preterm newborns to prevent 
death, bronchopulmonary dysplasia, or both is high and 
this modality is used routinely in developed countries. In 
addition, the quality of evidence for the use of nCPAP as 
an alternative to mechanical ventilation is high, making it 
particularly appealing in LMIC settings even though only 
two of the 29 studies reviewed are from such settings. 
Th  e intervention is strongly recommended, however 
optimal delivery systems, interfaces and optimal pressures 
must be elucidated. Further, ensuring adequate support 
services such as managing airleak syndrome will be 
important prior to widespread implementation.
Intravenous immune globulin (IVIG)
Preterm neonates are deﬁ   cient in immunoglobulins, 
particularly IgG, [334] and the use of non-speciﬁ  c, 
polyclonal intravenous immune globulin (IVIG) (normal 
human IgG immunoglobulin) has been advocated to 
prevent or treat neonatal infections.
A Cochrane meta-analysis reviewed 19 studies from 
diﬀ  erent parts of the world that compared IVIG with 
placebo [335] in approximately ﬁ  ve thousand preterm or 
low birth weight newborns. Th   e use of prophylactic IVIG 
reduced sepsis (RR 0.85; 95% CI 0.74-0.98), but did not 
signiﬁ  cantly reduce all-cause mortality (RR 0.89; 0.75-
1.05) or mortality due to infectious diseases (RR 0.83; 
95% CI 0.56-1.22). Th   e same authors also reviewed nine 
RCTs restricted to neonates who had a suspected 
infection during their initial hospital stay [336]. Based on 
six trials, there was a borderline reduction in overall 
mortality in the IVIG group (RR 0.63; 95% CI 0.40-1.00). 
Seven trials of newborns with conﬁ  rmed  infection 
showed IVIG did result in a statistically signiﬁ  cant reduc-
tion in mortality (RR 0.55; 95% CI 0.31-0.98). However, 
the authors identiﬁ  ed methodological problems, such as 
lack of allocation concealment, lack of blinding in out-
come assessment, high frequency of post-randomization 
exclusions and lack of long-term follow-up, and 
suggested further trials be conducted to conﬁ  rm or refute 
the eﬀ  ectiveness of IVIG treatment.[336] More recent 
trials on this subject are not available.
Assessment
Th   e level of evidence is high, but the intervention has a weak 
recommendation in favor of adoption. More infor  ma  tion on 
dosing, potential risks[337] and long-term follow-up is 
needed before IVIG may be widely recommended. Th  e 
following issues are of particular relevance to LMICs: 
feasibility (e.g., the need for cold storage and for intravenous 
administration); cost-beneﬁ   t analyses; and ensuring 
formulations include standardization of proper levels of 
antibodies against prevalent infectious agents.
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syndrome (RDS)
A single dose of bovine, calf, human or synthetic surfac-
tant to prevent RDS is associated with a decrease in 
neonatal mortality and chronic lung disease, or broncho-
pulmonary dysplasia (BPD) [338, 339]. Prophylactic use 
of surfactant is more eﬀ  ective than administration after 
RDS symptoms develop, but it is substantially more 
costly and beneﬁ  ts are limited to very preterm newborns 
(<30 weeks gestation) [340].
Rescue surfactant treatment provided within two hours 
of delivery, compared with later administration, is 
associated with decreases in neonatal mortality, chronic 
lung disease and chronic lung disease or death at 
36  weeks [341]. Th  ree to four doses of surfactant for 
preterm neonates appear to be more beneﬁ  cial  than 
single doses for prevention or treatment of RDS with 
respect to incidence of pneumothorax; however, 
diﬀ  erences in mortality were not statistically signiﬁ  cant 
in this recent meta-analysis [342]. Th  ese ﬁ  ndings are of 
particular relevance to LMICs, as treatment with 
surfactant within the ﬁ  rst two hours of life may reduce 
mortality while requiring treatment of a substantially 
smaller number of neonates than the prophylaxis 
approach. Antenatal steroids are shown to be synergistic 
with surfactant replacement [343]. Th   erefore, it is 
possible that with optimal antenatal steroid coverage 
fewer neonates would require intubation and those 
receiving surfactant therapy may further improve their 
outcomes.
Natural surfactants, compared to synthetics, result in 
reduced mortality and pneumothorax [344]. Clinically 
signiﬁ  cant  diﬀ   erences between porcine and bovine 
surfactants have not been consistently demonstrated 
[345, 346]. However, comparisons of natural surfactants 
to new synthetic surfactant preparations, which contain 
surfactant protein analogues, found no diﬀ  erences  in 
mortality at 36 weeks, chronic lung disease, the combined 
outcome of mortality or chronic lung disease, or 
mortality at one year [347, 348]. Synthetic forms of 
surfactant exhibit more temperature stability and have 
the potential for scaling up production to lower costs. 
Th   ese features are particularly relevant in LMICs.
Surfactant is administered to the newborn lung after 
endotracheal intubation, which is associated with 
signiﬁ   cant cost and potential morbidity. Alternative 
surfactant delivery systems have the potential to greatly 
improve access to and safety of this intervention in both 
LMICs and HICs. Attempts at nebulizing surfactants 
have been unsuccessful [345, 349]. More recently, 
surfactant instilled into the posterior pharynx is shown 
to be feasible without intubation and to improve lung 
function, yet further research is needed to assess the 
eﬃ   cacy of such an approach [350-352].
Assessment
Th   e quality of evidence for using surfactant replacement 
therapy to prevent or treat respiratory failure, broncho-
pulmonary dysplasia and/or death among preterm 
newborns is high and this modality is used routinely in 
HICs. Although only three of the 50 studies reviewed are 
from LMICs, the intervention is strongly recommended. 
However, multiple challenges remain and should be 
addressed prior to widespread implementation: identiﬁ  -
ca  tion of optimal dosing and delivery systems, develop-
ment of low-cost preparations, and reﬁ  ned techniques to 
identify high-risk newborns who may beneﬁ  t  from 
surfactant therapy.
Community-based packages of interventions
So far, this review was centered on standalone biological, 
behavioral or health care interventions. Community-
based strategies in LMICs, however, often combine 
several diﬀ  erent interventions, making it impossible to 
disentangle their individual eﬀ   ects. Here we review 
studies of community-based intervention packages that 
provide maternal and newborn care.
Nearly half of the world’s 124 million births that take 
place every year occur at home. In South Asia and sub-
Saharan Africa—the two regions with the highest 
neonatal mortality rates in the world—64% of the births 
take place at home. Most of these births are without 
skilled attendance. In these areas, the most promising 
short-term strategy for providing newborn care entails 
training and outﬁ  tting community health workers. Bhutta 
and colleagues conducted a thorough review of the 
literature on community-based interventions aimed at 
reducing perinatal and neonatal morbidity and mortality 
[353]. All six trials included in this review were from 
South Asia and had a signiﬁ   cant impact on newborn 
health. Similar studies were not available from other 
regions of the world.
Th   e classic studies of Bang and associates in Gadchiroli, 
India, showed an important impact of home-based care 
by trained village health workers, who provided antenatal 
care, managed birth asphyxia, hypothermia, neonatal 
sepsis and secured the care of preterm and low birth 
weight newborns. Th   is low-cost, sustainable intervention 
reduced case-fatality of neonatal sepsis, leading to a 71% 
reduction in perinatal mortality and a 62% reduction in 
neonatal mortality rates [274, 354-356].
In Nepal, a RCT evaluated the impact of a participatory 
intervention involving women’s groups convened by a 
female facilitator. During these sessions, local problems 
were identiﬁ  ed and possible solutions proposed. Women 
in the intervention clusters had more antenatal care, 
institutional deliveries and, skilled birth attendance, and 
hygienic care than those in the control areas. Th  ese 
changes were accompanied by signiﬁ  cant reductions in 
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(adjusted odds ratios 0.70, 95% C.I. 0.53-0.94 and 0.22, 
95% C.I. 0.05-0.90, respectively) [357].
In Sind, Pakistan, a RCT was conducted in which 
traditional birth attendants were trained and received 
disposable delivery kits, and female health workers made 
the connection of traditional services with health 
institutions. Women in the intervention communities 
had more antenatal care and were delivered more often 
with safe kits. Th  e odds ratio for perinatal mortality in 
the intervention areas was 0.70 (0.59-0.82) [142].
In a pilot randomized study in Pakistan, female health 
workers and traditional birth attendants received training 
in a package of community-based intervention for 
improving perinatal care. Th   e proportion of deliveries by 
skilled heath attendants increased in the intervention 
villages and there were signiﬁ  cant reductions in the rates 
of stillbirth and neonatal death [140].
Another recent RCT conducted in Bangladesh 
compared three groups: a home-care program (consisting 
of antenatal and post-natal home visits by community 
health workers who provided care directly to mothers and 
newborns), a community-care program (including group 
sessions on birth and newborn-care preparedness and 
promotion of careseeking from qualiﬁ  ed providers) and a 
comparison group. In the last 6 months of the 30 month 
intervention, the neonatal mortality was reduced by 34% 
in the home-care program (adjusted relative risk 0.66, 95% 
C.I. 0.47-0.93) relative to the comparison group [314]. No 
impact was observed in the community-care group.
Finally, a RCT conducted in Uttar Pradesh, India, 
entailed the comparison of three groups. Th  e control 
group received the usual maternal and newborn services; 
the ﬁ  rst intervention group received a preventive package 
of essential newborn care interventions, including birth 
preparedness, clean delivery and cord care, thermal care 
(with skin-to-skin contact), breastfeeding promotion, 
and training on recognition of danger signs; the second 
intervention group received the same basic package 
described above plus the use of a liquid crystal 
hypothermia indicator. Both control groups showed 
improvements in birth preparedness, hygienic delivery, 
thermal care, umbilical cord care, skin care, and 
breastfeeding. In comparison with the control group, 
neonatal mortality was reduced by 54% in the essential 
newborn care group (rate ratio 0.46, 95% C.I. 0.35-0.60) 
and by 52% in the essential newborn care plus Th  ermoSpot 
group (rate ratio 0.48, 95% C.I. 0.35-0.66) [315].
Assessment
Taken together, these six trials in South Asian countries 
strongly suggest that community-based programs, 
particularly those that provide maternal and newborn 
care by trained village health workers, may have a 
substantial impact in reducing stillbirth and neonatal 
mortality. Th   e quality of the evidence is high, and there is 
a strong recommendation for their implementation in 
settings where the vast majority of deliveries occur at 
home.
None of these trials reported impact on preterm 
deliveries. Also, trials from other regions of the world—
particularly sub-Saharan Africa—are urgently needed.
Research questions: development of interventions for 
preterm birth and stillbirth
Th  e review of the literature, summarized above, led to 
the identiﬁ  cation of over 100 research questions. Th  ese 
questions were analyzed and prioritized by workgroups 
at the International Conference on Prematurity and 
Stillbirth and will be addressed in a forthcoming Child 
Health and Nutrition Research Initiative (CHNRI) paper. 
Workgroup participants are leading international experts 
in the areas of maternal, fetal newborn and child health.
Conclusion
After reviewing 2,000 studies on more than 80 inter-
ventions, 21 preterm birth and stillbirth interven  tions are 
strongly recommended in LMICs. Each of these has high 
quality evidence it is eﬀ  ective in low-income settings. 
Th  is extensive review identiﬁ   es eight proven eﬀ  ective 
interventions for preventing stillbirth in LMICs and 11 
for improving the survival of the preterm neonate. Only 
two available interventions are strongly recom  mended 
for preventing preterm birth.
Additional research must be conducted on many other 
promising interventions before they can be recom-
mended for scale-up in LMICs. Additional research on 
the cost-eﬀ   ectiveness of these interventions is also 
needed, as it was outside the scope of this analysis. It 
must also be noted that many interventions not strongly 
recommended for these speciﬁ   c outcomes are indeed 
recommended for other related maternal and child health 
outcomes. A summary of these ﬁ  ndings, based on the 
GRADE assessments, is provided in Table 3. Th  e next 
article discusses scale-up of proven interventions, and 
addresses delivery in the context of maternal, newborn 
and child health [3].
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